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ABSTRACT 
The hepatitis C virus (HCV) is a major global health problem with around 130-150 million individuals 
chronically infected and it is estimated that 2 millions are newly infected each year. The HCV 
infection is one of the major causes of liver disease and the infection is characterized by a slow and 
silent progression. Patients infected with HCV have an increased risk of developing fibrosis, cirrhosis 
and hepatocellular carcinoma.   
The effectiveness of new treatments has drastically improved during the last years and the cure rate is 
today around 90 %. However, several obstacles remain to be solved. Firstly, the treatment is 
associated with high costs. Secondly, there are still uncertainties whether patient groups such as 
children, pregnant women and treatment-experienced patients will be eligible for this treatment. 
Finally, the direct-acting antiviral (DAA) treatment does not protect against a re-infection. Also, only 
around 10 % of all chronic HCV carriers have access to treatment and the highest prevalence of HCV 
are seen in developing countries, which highlights the need of alternative less-expensive treatment 
strategies.  
In this thesis we developed and characterized new treatments strategies for HCV based on genetic 
vaccines and re-direction of T cells. We utilized the non-structural (NS) 3/4A and 5A proteins of HCV 
as vaccine antigens and as targets for re-directed T cells. Both the NS3/4A and NS5A proteins have 
essential functions in HCV life cycle.  
We generated an NS5A-based DNA vaccine and performed detailed characterization of its in vivo 
immunogenicity. We have previously developed a DNA vaccine based on NS3/4A that effectively 
primes immune responses in vivo. A codon optimized NS5A vaccine sequence was delivered 
intramuscularly in combination with in vivo electroporation for efficient uptake. The DNA vaccine 
activated NS5A-specific immune responses in both wild type and NS5A-transgenic (Tg) mice, with 
dysfunctional HCV-specific T cells. The vaccine primed responses were functional in vivo as 
evidenced by protection against in vivo tumor growth of NS5A-expressing cells. Furthermore, the 
vaccines were also used to develop NS3- and NS5A-specific T cell receptors (TCRs). Both the 
NS3/4A and NS5A TCRs were able to inhibit HCV RNA replication in vitro albeit using different 
mechanisms, possibly related to differences in the T cell avidity. The NS3/4A and the NS5A vaccines 
activated distinct HCV-specific immune responses. The NS3/4A vaccine was dependent on IFNγ and 
CD8+ T cells but not CD4+ T cells, whereas the NS5A vaccine was dependent on both CD4+ and 
CD8+ T cells but not on IFNγ. This is consistent with high-avidity NS3-specific TCRs inducing 
polyfunctional T cells, as compared to the low-avidity NS5A TCRs inducing monofunctional T cells. 
Finally, we analyzed the possibility to improve the intrinsic immunogenicity of the NS5A vaccine. We 
have previously showed that the immunogenicity of a NS3/4A-based vaccine could be significantly 
increased by co-expression with IL-12 and the addition of heterologous sequences from hepatitis B 
virus core antigen (HBcAg). However, the immunogenicity of NS5A was enhanced by addition of 
HBcAg sequences, but not co-expression of IL-12. 
In conclusion, we have developed and evaluated new potential therapeutic interventions for the 
treatment of chronic HCV infection. Although the effective DAA treatment is available, it is clear that 
alternative treatment strategies are needed. These should be associated with lower costs and 
preferentially induce a post cure immunity that protect against re-infection. 
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1 INTRODUCTION TO HEPATITIS  
The liver is a vital organ for humans, which is located in the upper right part of the abdomen. Several 
important functions as protein syntheses, production of compounds necessary for digestion, 
detoxification and many others are carried out by the liver.  
The cause of hepatitis, which means inflammation (greek itis) of the liver (greek hepar), are several 
factors such as viral infection, bacterial infection, metabolic disorders, alcohol, toxins drugs, 
chemicals, etc. Until now five viruses have been identified to infect the liver, hepatitis A, B, C, D and 
E. There are also other viruses that may infect the liver such as Epstein Barr virus (EBV), 
Cytomegalovirus (CMV), Yellow fever, Ebola, Dengue and Adenoviruses.  
The primary site of hepatitis virus replication is the hepatocytes that occupy approximately 80% of the 
liver volume. The entry of the liver is via the blood stream, which gives the virus access to the 
hepatocytes and can cause an acute infection. The hepatitis infection can be asymptomatic or 
symptomatic with common symptoms such as jaundice or yellowish skin (bilirubin in the blood), 
fatigue, nausea, myalgia, stomach pain, vomiting and fever. The acute infection of hepatitis often 
results in measurable elevated levels of liver enzymes in the blood. A chronic infection is a persistent 
viral infection for more than six months and this chronic phase proceeds as either asymptomatic or 
symptomatic where the symptomatic often is associated with active inflammation and increased risk 
of cirrhosis and hepatocellular carcinoma (HCC, liver cancer). Although all five known hepatitis 
viruses infect the liver they differ in genome, structure and also transmission routes.  
1.1 HEPATITIS A VIRUS 
The hepatitis A virus (HAV) was discovered in 1973 and belongs to the Picornaviridae virus family 
(1). It is a single stranded RNA virus transmitted via the fecal-oral route and causes only acute 
infection. The incubation time is 2-6 weeks and the infection is often symptomatic. There are both 
passive immunization (immunoglobulins) and prophylactic vaccination available (2). 
1.2 HEPATITIS B VIRUS 
The hepatitis B virus (HBV) was discovered in 1965 and belongs to the Hepadnaviridae virus family 
(3). It is a partially double stranded DNA virus transmitted via contaminated blood, sexual or vertical 
transmission. The hepatitis B virus has evolved a strategy of causing tolerance in infants during the 
neonatal development. The HBeAg, which is not required for replication, assembly or infection, is 
secreted and can pass through the placenta, enter the blood stream of the fetus and induce tolerance. 
During the delivery the infant gets infected and due to the already tolerized immune system 90 % of 
the infants develop chronic hepatitis compared to less than 10 % of the adults (4).  It is estimated that 
a third of the world’s population has been exposed to HBV and that approximately 350 million 
individuals are chronically infected. Chronic HBV is treated with interferon-α or antivirals such as 
entecavir and tenefovir (5). A prophylactic vaccine with effective protection is available (6) 
1.3 HEPATITIS C VIRUS 
The hepatitis C virus (HCV) was discovered 1989 and belongs to the flaviviridae virus family (7). It is 
a single stranded RNA virus transmitted mainly via contaminated blood. The infection leads into a 
 2 
chronic infection in around 80 % of the acute cases and approximately 130-150 million infected 
people worldwide. Hepatitis C virus can also cause chronic infection and will be discussed in grater 
detail later.  
1.4 HEPATITIS D VIRUS 
The hepatitis D virus (HDV) or “deltavirus” was discovered in 1977 and belongs to the genus 
Deltavirus (8). It is a single stranded RNA virus lacking polymerase and envelope protein. Hepatitis D 
virus is therefore dependent of a human RNA-polymerase to replicate and also the HBV surface 
antigen to generate infectious viral particles. Hepatitis D virus is transmitted either as a co-infection 
with HBV or as a superinfection where the person is already chronically infected with HBV and at a 
later stage gets infected with HDV. A co-infection or superinfection is associated with more severe 
infection than HBV alone (4). Treatment for HDV are the same as for HBV. 
1.5 HEPATITIS E VIRUS 
The hepatitis E virus (HEV) was discovered 1983 and belongs to the Hepeviridae virus family (9). It 
is a single stranded RNA virus transmitted via the fecal-oral route and causes only acute infection. The 
incubation time is 3-8 weeks and the infection is often symptomatic. There is no specific treatment or 
vaccine available for HEV. 
 
2 HEPATITIS C VIRUS  
2.1 HISTORY  
In the 1970s serological testing for hepatitis A and hepatitis B virus were developed and it was 
revealed that an not yet discovered virus causing hepatitis were existing, non-A and non-B hepatitis.  
In 1989 the genome of non-A and non-B hepatitis were cloned and characterized after experimental 
infection of chimpanzee and at the same time a serological test were developed (7, 10). The virus was 
named hepatitis C virus (HCV) and were similar in structure to flaviviruses (e.g. Dengue fever, West-
Nile virus, Yellow fever virus) and pestiviruses (e.g. bovine viral diarrhea virus) in the Flaviviridae 
family and was therefore classified in the same family in the genus of Hepacivirus (11). Since the 
early 1990s, all blood used in medical centers are screened for HCV. In high-income countries, the 
transmission is almost exclusively occurring in intra venous drug users (12).  
2.2 EPIDEMIOLOGY 
The world’s health organization (WHO) estimated that the worldwide prevalence of chronic HCV 
infection is around 130-150 million or approximately 2% of the world population (13). The country 
with the highest prevalence of HCV is Egypt with 10-20% of the population infected due to unsterile 
injection equipment during treatment of the general population against the parasite schistosomiasis in 
the 1980s (14-16). Prevalence of HCV in Europe is around 8 million people (2-3,5%) and in Sweden 
around 40,000 (0,5%) (17-19).  
   3 
 
Figure 1. Schematic drawing of the hepatitis C virus genome and proteins. 
 
2.3 HCV GENOME 
The hepatitis C virus is consisting of a single stranded positive sense RNA molecule encapsulated in a 
spherical particle of 55-65 nm in diameter (20). The viral RNA genome is around 9,6 kb and encodes 
for one single open reading frame (ORF) that are translated into one polyprotein of approximately 
3000 amino acids (7). Untranslated regions (UTR) in the 5´and 3´ ends of the genome contain 
essential secondary RNA structures for the viral replication. The 5´ UTR includes an internal 
ribosome entry site that initiates the translation of the polyprotein, which is then processed by host and 
viral proteases to individual structural proteins (core, envelope 1 and 2) and non-structural (NS) 
proteins (p7, NS3, NS4A, NS4B, NS5A and NS5B) (Figure 1). The core (c) protein is building up the 
nuclear capsid and is involved in regulation of functions in translation, RNA replication and assembly 
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of virus particles (21). The envelope (E) protein E1 and E2 are glycoproteins that are essential for 
receptor binding and receptor mediated endocytosis (22, 23). The p7 protein is an integral membrane 
protein with the activity of an ion-channel that it is required for formation of infectious virions (24, 
25). The NS2 protein catalyzes the cleavage between NS2-NS3 in the polyprotein (26, 27) and NS3 
are responsible for the cleavage of the polyprotein down stream of NS3 to the individual proteins. The 
NS3 protein has beside the function as a serine-protease (N-terminal domain, 180 aa) also a 
helicase/NTPase function (C-terminal domain, 442 aa), binding and unwinding the secondary 
structures of the viral RNA (28, 29). The NS3s function is dependent on the cofactor NS4A and its 
membrane-anchoring domain to be localized at the ER membrane and also to stabilize the protease 
from proteolytic degradation (30-32). The NS3 protein is also known for inhibiting the host cell innate 
immune response against HCV, discussed in “Immune response and immune evasion in HCV 
infection”. The NS4B protein is crucial for the RNA replication and formation of the membranous 
web at the ER membrane during viral replication (33-35). The NS5A is a multifunctional 
phosphoprotein with still not fully understood function/s. It is anchored to the ER membrane, essential 
for viral RNA replication, important for assembly of viral particles and interacts with several host and 
viral proteins (36-38). The NS5A protein is also involved in modifying the immune response to the 
infected cell, discussed in section: “Immune response and immune evasion in HCV infection”. The 
NS5B is the RNA-dependent RNA polymerase (RdRp) associated to the ER membrane and is the 
component in the replication complex catalyzing the process of duplicating the viral RNA (39, 40).  
 
Figure 2. The estimated prevalence of HCV infection and the distribution of HCV genotypes across the world. 
Adapted by permission from Macmillan Publishers Ltd: [Nat Rev Gastroenterol Hepatol.] (41), copyright 
(2013). 
2.4 GENOME DIVERSITY 
The genome of hepatitis C virus is highly variable due to fact that the RNA-dependent RNA 
polymerase lack proof-reading activity. The high HCV replication rate of 1010-1013 new virus particles 
per day result in a mutation rate of 103 nucleotide substitutions per nucleotide and year. The high 
variability in the genome has resulted in 7 different genotypes (1-7) and many subtypes (a, b, c, etc.) 
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(Figure 2) (41). Genotype 1 represents over 50 % of all HCV infections and is distributed worldwide. 
Also genotype 2 is found worldwide. Genotype 3 are most common in southern Asia but also 
distributed worldwide. Genotype 4 is associated to northern Africa, genotype 5 in South Africa and 
genotype 6 in Asia. Genotype 7 has recently been identified in an emigrant from central Africa (42). 
The genotypes differ from each other with 30-35 % and the subtypes can vary between 20-25 % (43).  
Due to the mutation rate of HCV there is also variations within the viral genome of the same patient. 
This is referred as quasispecies and can vary between 1-9 %. There are regions of the HCV genome 
that are less variable such as the 5´UTR with nucleotide sequences more than 90 % homology among 
genotypes. Other regions with low variability are the core, NS3 and parts of NS5 (44). The segment 
with the highest variable sequence is the hyper variable region in the E2 protein with as much as 50 % 
diversity among genotypes. 
2.5 VIRAL LIFE CYCLE 
The hepatitis C virus only infects humans and chimpanzees where the hepatocytes are the primary 
target cell for propagation but there have been reports that also dendritic cells, B cells and other cells 
can be infected but it is debated whether these cells really can propagate the virus.  
2.5.1 Binding and entry 
It has been shown that HCV is associated with low-density lipoprotein (LDL) and very low-density 
lipoprotein (VLDL) when circulating in the blood. The first receptors that mediate the entry are the 
LDL receptor and glycosaminoglycans (GAG) but the exact role still remains to be determined (45, 
46). The E2 protein then binds CD81 (tetraspanin) and scavenger receptor B-1 (SR-B1) followed by 
interaction with the tight junction proteins claudin-1 (CLDN1) and occluding (OCLN) to enter the 
target cell (47-50). Other receptors necessary for entry is cholesterol absorption receptor Niemann-
Pick C1-like 1 (NP1L1), epidermal growth factor receptor (EGFR) and epherin receptor type A2 (51, 
52). It has been shown that it is possible to make mouse hepatocytes susceptible to HCV entry by 
making the mice transgenic for the human CD81 and OCLN (50). After receptor binding, fusion of 
the viral envelope and the cell membrane takes place followed by endocytosis mediated by the protein 
claterin (53). The viral genome is then released into the cytosol by fusion of the endosomal membrane 
and viral envelope (Figure 3) (54).  
2.5.2 Translation and processing of protein 
The released single stranded RNA with positive sense is translated via the internal ribosome entry site 
(IRES) which means that the translation is a cap-independent translation mediated by the IRES (55). 
The translated polyprotein is then processed by host proteases and the viral NS2/3 protease (Figure 3) 
(56).  
2.5.3 RNA replication 
The replication occurs in a structure called the membranous web. This is a structure that is derived 
from the ER membrane and the NS4B protein has a central role in the formation of the membranous 
web (33). The RNA-dependent RNA polymerase (RdRp) or NS5B is the essential protein and the 
catalytic component of the replication complex. The NS3 protein with helicase function unwinds the 
secondary structures on the viral RNA and the NS5B protein is synthesizing the negative single 
stranded RNA out of the positive stranded RNA genome (28, 29). The synthesized RNA strand with 
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negative sense is then used as a template for generation of new viral RNA genome with positive sense 
(Figure 3).  
2.5.4 Assembly and release 
It has recently been shown that the assembly of the viral proteins and RNA occurs in the ER 
membrane by both viral and host factors (57). The particle formation where core units are building up 
the nucleocapsid incorporating viral RNA is arranged in co-localization with lipid droplets (58, 59). 
The formed virus particles are then surrounded by membrane from the ER, in which heterodimers of 
the glycoprotein E1 and E2 are embedded. The virus particle is then released in a secretory pathway 
from the cell (Figure 3).  
 
Figure 3. Illustration of the HCV life cycle. Adapted with permission from (60). 
 
2.6 HCV INFECTION  
Hepatitis C virus is a blood-borne virus where the main transmission route differs between high-
income and low-income countries. In high-income countries the main transmission route is via 
contaminated needles and syringes in the group of intra venous drug users. In low-income countries it 
is instead nosocomial transmission that is the main rout of transmission such as blood transfusions and 
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transplantations. Sexually and vertical (mother to child) transmission of HCV is rare but still a risk of 
transmission as well as body piercing and tattooing. In approximately 80 % of the cases the HCV 
infection turns chronic meaning that the infection of the liver has been persistent over a period of six 
months. Spontaneous resolution of the infection occurs in approximately 20 % of the cases often 
without any or with mild symptoms (61). The chronic infection is characterized by elevated levels of 
alanine aminotransferase (ALT), anti-HCV antibodies and detectable viral RNA. The inflammation of 
the liver progresses gradually to fibrosis and after 10-30 years of chronic HCV infection around 20 % 
of the patients will develop cirrhosis with an increased risk of developing hepatocellular carcinoma 
(Figure 4). The acute infection is difficult to recognize because there are no or non-specific 
symptoms. Thus, acute HCV infection is only treated if the individual is confirmed HCV positive with 
known time point for exposure, for example accidental needle stick. If the patient is treated with IFNα 
monotherapy during the acute phase most resolve the infection (62, 63). Resent development of direct 
acting antiviral drugs have revolutionized the treatment of chronic HCV infection with cure rates over 
90 %, discussed in more detail under “Treatment”.  
 
 
Figure 4. Flow chart over of the clinical course of HCV infection.  
 
2.7 IMMUNE RESPONSE AND IMMUNE EVASION IN HCV INFECTION  
The immune system is divided into two separate parts, innate and adaptive. The first line of defense 
towards pathogens is the anatomical barrier in the case of HCV it is skin, mucous membrane and eyes 
that needs to be penetrated or passed through to get in contact with the blood flow and continue to the 
liver. In the liver, the innate immune system reacts with Kupffer cells (liver macrophages), natural 
killer cells (NK), natural killer T cells (NKT) and IFN response from hepatocytes and other cells. The 
adaptive immune system is activated later and consists of CD4+ and CD8+ T cells and B cells. The 
inherent tolerogenicity of liver and its role in regulating innate and adaptive immunity may cause 
weak or no responses to invading pathogens instead of priming a strong immune response to the 
pathogen. In addition, HCV has evolved different strategies to avoid the host immune response, which 
will be discussed below.  
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Figure 5. Illustration of the innate immune activation during HCV infection. Adapted by permission from 
Macmillan Publishers Ltd: [Nat Med.] (64), copyright (2013). 
 
2.7.1 Innate immune response 
2.7.1.1 Intracellular immune activation upon virus recognition 
Pattern recognition receptors (PRR) like toll like receptors (TLR) and retinoic acid-inducible gene 
(RIG)-I are important in the response against virus infection by recognition of pathogen-associated 
molecular patterns (PAMPs). TLR-3, protein-kinas R (PKR) and RIG-I are all present in hepatocytes 
and involved in sensing the viral replication. Upon HCV infection the double stranded RNA as a 
result of the viral replication is recognized by these receptor. The activation of PKR, RIG-I and TLR-3 
leads to a signaling cascade (PKR and RIG-I via mitochondrial antiviral signaling protein (MAVS) 
and TLR-3 via TIR domain-containing adapter inducing IFNβ (TRIF)) with induction of interferon 
regulatory factor (IRF)-3, NF-κB and production of type I and III IFNs (IFNα, β and λ), 
proinflammatory cytokines and chemokines, antiviral genes and apoptotic signal (64). This affects the 
infected cell and also the neighboring cells via the IFN signaling that induces the JAK/STAT pathway 
which leads to induction of a antiviral state and limits possibility for the virus to spread from cell-to-
cell (Figure 5) (65). In the chronic infection these signaling pathways are blocked or altered by HCV 
using different strategies. The HCV NS3/4A protein is involved in interrupting the RIG-I signaling by 
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cleavage of MAVS. This block down stream signaling pathways and induction of NF-κB and IRF-3, 
which causes a lack of production or secretion of INFβ or antiviral genes (66, 67). The HCV protein 
NS5A are also involved in disturbing the innate immune system of HCV by interfering with PKR. The 
NS5A protein is inhibiting the PKR and the functions that PKR has upon sensing double stranded 
RNA. These functions are important for the innate immune system to inhibit translation, induction of 
apoptosis, type I interferons and antiviral genes. This evasion of the antiviral response has been 
described as an IFN sensitivity determining region (ISDR) dependent way of inhibition. The NS5A 
protein can also inhibit antiviral activity of IFN through interaction with 2’5’ oligoadenylate 
synthetize (OAS) and by that via an ISDR non-dependent way (68-70). In addition to NS5A, also E2 
and the IRES in the 5’UTR has been described to inhibit PKR and the downstream antiviral signaling 
(71, 72). Additionally, HCV has also developed strategies to render the host cell more tolerant against 
TNFα mediated apoptosis by the NS3/4A and NS5A proteins interfering with the TNFα signaling 
(73-75). Furthermore, the core protein of HCV is also involved in affecting the innate immune system 
by interfering with the STAT pathway and thereby inhibiting interferon stimulating genes (ISG) (76).  
2.7.1.2 Natural killer (NK) cells  
The liver consists of an unusual high frequency of NK cells with 30-50 % of the lymphocytes being 
NK cells compared to 5-20 % in the peripheral blood, which indicates the importance of this cell type 
in the liver (77). Natural killer cells play an important role in the rapid response to pathogens and 
tumors. The NK cells have the ability to rapidly kill target cells without antigen recognition or prior 
activation. Instead the NK cell recognizes abnormal levels of major histocompatibility complex 
(MHC) class I and/or stress induced molecules on the target cell (78, 79). The NK cells are present in 
two subgroups, a more mature form and a less mature form. The more mature form of NK cells has 
high cytotoxic effect with the ability of activating cell death receptors that mostly involve the tumor 
necrosis factor (TNF) superfamily such as Fas ligand (FasL) and TNF-related apoptosis-inducing 
ligand (TRAIL), TNFα and release of perforin and granzyme. The less mature variant of NK cells has 
the capacity of secreting granulocyte-macrophage colony-stimulating factor, IFNγ, TNFα, interleukin 
(IL)-5, IL-10, IL-13 and tumor growth factor (TGF)-β (80). During chronic HCV infection the NK 
cells have a dysfunctional phenotype and the overall number of NK cells are also decreased (81, 82). 
Beside that dysfunctional NK cells may not be able to directly kill HCV infected hepatocytes, their 
dysfunction also affects the cytokine production, which may also affect other cells ability to eradicate 
HCV. The Th2 type of response with decreased IFNγ production and increased production of IL-10 
and TGF-β also influence and diminish the function of dendritic cells and T cells (83-85).  
2.7.1.3 Natural killer T (NKT) cells  
Natural killer T cells are a heterogeneous type of T lymphocyte that co-express the T cell receptor 
(TCR) and NK cell markers. These cells have both effector and immune regulatory function (86). The 
NKT cells have the ability to recognize both self and foreign lipids and glycolipids via the MHC class 
1b molecule (CD1). Activation of NKT cells stimulates expression of FasL, secretion of cytokines like 
IL-4, IFNγ, TNFα and activation of other cells like dendritic cells (DC) and NK cells. This is 
suggesting that NKT cells may be involved in both eradication of virally infected cells and immune-
mediated liver damage (87). Natural killer T cells have been shown to be reduced in numbers during 
chronic HCV infection and following sustained responses after IFNα/ribavirin treatment the number 
of NKT cells are increased (81, 88, 89). This indicates that the NKT cells are involved in the clearance 
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of HCV but on the other hand there has also been reports correlating the degree of fibrosis and liver 
damage with the frequency of activated NKT cells.  
2.7.1.4 Dendritic cells (DC) 
Dendritic cells are the connection between the innate and adaptive immune response and also the 
major antigen-presenting cell in the body. Dendritic cells are recognizing viral infection via pathogen-
associated molecular patterns (PAMPs) after uptake of the pathogen and then migrate into the lymph 
nodes and present the antigen to specific T cells. Two main subgroups of DC exist, myeloid DCs 
(mDCs) and plasmacytoid DCs (pDCs). Myeloid DCs are mainly associated with expression of TLR-
3 and 8, antigen processing and presentation as well as secretion of IL-10 and IL-12. Plasmacytoid 
DCs are instead expressing TLR-7 and 9 as well as IFNα production. In patients with chronic HCV 
the mature function seems to be impaired as well as the frequency of mDC and pDC are reduced (90, 
91). Myeloid DC in chronically infected patients are also impaired in the capacity of stimulating CD4+ 
T cells and in the secretion of IL-12. The mDCs have increased expression of the exhaustion molecule 
programmed death (PD)-1 and the ability to produce IL-10 is increased as well as priming of IL-10-
producing T cells (90, 92). These mDCs also seems to have the ability to impair the priming of HCV-
specific T cells by inducing proliferation of regulatory T cells (Tregs) (93). The pDC in chronically 
infected HCV patients are also impaired regarding the function of producing IFNα (90, 94) 
2.7.1.5 Kupffer cells (KC) 
The liver is harboring a large group of cells important for phagocytosis and antigen presentation. This 
population is a type of macrophages only present in the liver and termed Kupffer cells (KC). The KCs 
are expressing high levels of CD80, CD40 and MHC class II molecule indicating the phenotype of a 
professional antigen-presenting cell and are upon phagocytosis of pathogens activated by TLRs as in 
hepatocytes and results in production of type I and III IFN as well as production of IL-1, IL-6 and 
TNFα (95). During chronic HCV infection the Kupffer cells express increased levels of galectin-9, 
which is the ligand for the T cell immunoglobulin domain and mucin domain protein (TIM)-3. The 
galectin-9 is of importance due to its effect on the expansion of Tregs, reductions of CD4+ T cells and 
apoptosis of CD8+ T cells and thereby the suppression of the HCV-specific T cell response (96). It has 
been shown that macrophages during chronic HCV infection are linked to impairment of IL-12 
production, which is a key cytokine in the innate and adaptive immune response regarding 
differentiation of T cells and secretion of IFNγ and TNFα (96). 
2.7.2 Adaptive immune response 
The adaptive immune response is consisting of B cells that produce antibodies (e.g. plasma cells) and 
T cells. T cells are divided into two main groups, CD4+ T cells (T helper cells, Th) and CD8+ T cells 
(T effector cells, CTL). The adaptive immune system is activated during HCV infection by the 
infected hepatocytes or by specific antigen presenting cells (APC) like dendritic cells (DC), 
macrophages and B cells.  
2.7.2.1 Activation of T cells 
Endogenous pathway: In infected hepatocytes the viral proteins are degraded and processed in the 
cytosol as for all endogenous proteins. The proteasome processes the protein to peptides (8-10 amino 
acids) that are transported via the transporters associated with antigen processing (TAP) into the ER 
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where synthesized MHC class I are located and can recognize and bind the peptide. The peptide-MHC 
class I complex are then transported via the golgi apparatus to the cell surface were the peptide is 
presented to CD8+ T cells. The CD8+ T cells binds the MHC class I with its T cell receptor (TCR) and 
the CD8 molecule as co-receptor, which results in a signaling cascade activating the effector function 
(Figure 6a). (97)  
 
 
Figure 6. Illustration of antigen-processing and presentation via endogenous pathway (a), exogenous pathway 
(b) and by cross-presentation (c). Adapted by permission from Macmillan Publishers Ltd: [Nat Rev Immunol.] 
(98), copyright (2001). 
Exogenous pathway: The activation can also occur via APCs (exogenous pathway) where dendritic 
cells, macrophages and B cells are engulfing cell or cell debris from apoptotic, necrotic or infected 
cells. The antigen that enters the cell from the exogenous pathway are processed into 13-18 amino 
acid long peptides in endosomes which are then fused with exocytic vesicles from the golgi apparatus 
encapsulating MHC class II molecules. Here MHC class II recognize and binds peptide, which are 
then transported to the cell surface where MHC class II can present the peptide for CD4+ T cells. The 
CD4+ T cells are recognizing the MHC class II via the TCR receptor and the CD4 molecule as co-
receptor (Figure 6b). (97) 
Cross-presentation or cross-priming: Exogenous antigen can also be presented on the MHC class I 
to CD8+ T cells by cross-presentation. This occurs in DCs, which are professional antigen presenting 
cells and have the capacity of engulfing exogenous antigens and instead of having them processed by 
the exogenous pathway the antigens are released from the vesicle to the cytosol, and thereby entering 
the endogenous pathway and are presented on the MHC class I (Figure 6c). (97)  
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2.7.2.2 T cells 
The T helper cells (Th) are activated by the exogenous pathway via the interaction between MHC 
class II and CD4+ T cells. The activated CD4+ T cells are then differentiating to either Th1 or Th2 
cells characterized by cytokine secretion and function. The Th1 cells induce cellular immune 
responses by secretion of IL-2, IL-12, IFNγ and TNFα. The activated effector cells in a Th1 type of 
immune response are CD8+ T cells or cytotoxic T lymphocytes (CTLs) and NK cells with the effector 
function of killing target cells using granzyme, perforin and/or the death pathway (Fas-FasL). The 
effector function of CD8+ T cells is not restricted to the cytolytic functions mentioned above but also 
non-cytolytic effector functions mediated by secretion of cytokines as IFNγ and TNFα. The Th2 
response is characterized by activation of the humoral immune response, represented by the B cells 
expressing/secreting antibodies upon secretion of IL-4, IL-5, IL-6 and IL-13. CD8+ T cells recognizes 
antigen either by presentation of the MHC class I via the endogenous pathway or by cross-
presentation and thereafter differentiate into effector cells (CTLs). (97) 
Even though the HCV infection results in high levels of HCV replication the HCV-specific T cells 
first appears 4-8 weeks after the primary infection. Why the response is delayed is not completely 
understood but may be associated with the tolerant environment in the liver (99). Another explanation 
is the capability of HCV to avoid the innate immune system (discussed later). Resolution of acute and 
chronic HCV infections are associated with robust memory CD4+ and CD8+ T cells that have broad 
specificity to the HCV protein; core, NS3, NS4 and NS5. In addition, these individuals have increased 
plasma levels of IL-21 (100-104). It has also been shown that control of HCV infection is associated 
with a polyfunctional T cell response producing IFNγ and IL-2 (105). In patients who have 
spontaneously cleared an acute HCV infection, the CD4+ and CD8+ memory T cells could be detected 
in peripheral blood for up to 20 years in humans and 7 years in chimpanzees (106, 107). The 
importance of both CD4+ and CD8+ T cells has also been confirmed by depletion studies. Antibody-
mediated depletion showed that in the absence of CD4+ T cells, the CD8+ T cells could control the 
viral replication initially, however low levels of viremia could still be detected and the functional 
CD8+ T cells vanished (108). If instead the CD8+ T cells were depleted the control of the viremia was 
impaired (106).  
In chronic HCV infection the HCV-specific T cells are impaired in regards to several aspects. The 
CD4+ T cells response that is critical for a sustained HCV-specific CD8+ T cell response is often weak 
and production of IL-2 is reduced (109, 110). The cytotoxic effector function and the CD8+ T cell 
proliferation are impaired as well as the production of IFNγ (111, 112). It has been shown that HCV-
specific CD8+ T cell responses during chronic infections are weak or undetectable in peripheral blood, 
whereas detectable levels are found in the liver characterized by increased expression levels of 
molecules associated with exhaustion (high PD-1, low CD127) (113, 114). Molecules TIM-3, PD-1 
and cytotoxic T cell antigen 4 (CTLA-4) are associated with down-regulation of the cellular immune 
response. They are all highly expressed on intrahepatic HCV-specific CD8+ T cells during chronic 
HCV infection but absent on CD8+ T cells specific for cytomegalovirus or on CD8+ T cells from 
patients who have resolved the HCV infection after antiviral treatment (115). Interestingly, the HCV-
specific production of IFNγ, IL-2 and TNFα as well as the expansion of CD4+ T cells could be 
restored by blocking of PD-L1/2, IL-10 and TGFβ (116). Furthermore, the functionality of T cells 
differs depending of the type of antiviral treatment. It has been shown that patients treated with PEG-
IFNα/RBV still have dysfunctional and exhausted HCV-specific CD8+ T cells (117). In contrary, 
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suppression of HCV replication by IFN-free treatments restores the HCV-specific T cell response 
during and after cure (118).  
Regulatory T cells (Tregs) has several important mechanisms to down-regulate the immune response 
such as expression of IL-10, TGFβ, inhibitory molecules (PD-L1, galectin-9 and CTLA-4). The levels 
of CD4+/CD25+ T cells has been demonstrated to increase during chronic HCV infection and 
decreased to the same levels as healthy controls after cure (119, 120). Regulatory T cells have been 
described to alter the adaptive immune system during chronic HCV infection and are therefore 
believed to play an important role to maintain the infection. 
2.7.3 Immune evasion   
Beside the strategies mentioned above HCV may also escape the immune system by immune evasion 
due to the high mutation rate in the HCV genome. The NS5B protein or the RNA-dependent RNA 
polymerase lacks proofreading activity and this in combination with the high rate of viral replication 
causes introduction of mutations in the viral genome. There are several ways of how the introduced 
mutations can cause immune escape. The introduced mutations may lead to differences in the 
processed peptides after proteasomal degradation, which may result in that T cells recognize different 
peptides/epitopes (121). Mutations in epitopes may also result in loss of MHC peptide-binding or that 
the TCR do not recognize the epitopes. This results in that epitopes cannot be presented by the 
infected cell nor targeted by the T cells (122, 123). Mutations are an important mechanism for HCV to 
escape the host immune system, which has been shown with correlation between mutated CD8+ 
epitopes and persistent infection as well as correlation between wild-type (non-mutated) CD8+ T cell 
epitopes and clearance of the infection (124-126). At the same time as the mutations can help the virus 
escape from the immune system it can also affect the virus ability to replicate and produce new 
infectious viral particles (viral fitness). If a mutation affects the viral fitness too much that variant of 
the virus will vanish due to other virus variants with higher viral fitness. Some escape mutations is 
therefore less likely to appear in nature (127). 
2.8 MODEL SYSTEMS FOR HCV 
2.8.1 In vitro models 
In the past, in vitro research has been limited due to lack of cell culture systems susceptible for HCV 
infection, replication and virus production. Primary hepatocytes from humans and chimpanzees have 
been utilized but only with limited success. The primary cells only allowed for low level of 
replication, a short life span (few passages) and contamination problems (128). Despite the best of 
efforts, for many years researchers were unable of using robust and reliable cell culture systems. In 
addition, numerous immortalized cell lines have been studied over the years without sufficient results. 
The current available cell culture systems are described below. 
2.8.1.1 The sub-genomic replicon model 
Ten years after the discovery of HCV the first replicon model was established as a sub-genomic 
replicon harboring the non-structural proteins essential for replication (129). The year after, a replicon 
system containing the complete HCV genome was established (130). The replicon system allowed 
studies of host-viral signaling pathways and to study how mutations affect HCV replication. Adaptive 
mutations promoting HCV replication were found in the NS3, NS5A and NS5B proteins, which 
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strongly increased the levels of RNA replication (130-132). The sub-genomic replicon system has 
been invaluable for development and screening of HCV direct-acting antiviral drugs. However, the 
replicon system does not allow studies of viral entry and assembly.  
2.8.1.2 The HCVpp model 
The HCV pseudoparticle (HCVpp) model was developed to study entry and fusion of HCV into cells. 
The HCVpp is based on the retroviral proteins Gag and Pol, involved in the packaging of RNA and 
budding of virus particles, using the HCV glycoproteins as membrane of the produced virus particles. 
Human embryonic kidney cells (293T) were transfected with three vectors. The first vector includes 
retroviral Gag and Pol. The second vector codes for a reporter gene (luciferase or GFP). The third 
vector encodes for the HCV proteins E1 and E2. Pseudoparticles produced in 293T cells could then be 
used for infection of Huh-7 cells and this model became soon essential for studying neutralization and 
fusion mechanisms in vitro (22). This model has been a valuable tool in identification of the HCV co-
receptors Claudin-1 and Occludin. It has been shown, by using this model, that monoclonal antibodies 
against E1 and E2 protein as well as sera from infected patients could neutralize entry of the 
pseudoparticles (22, 53, 133). The HCVpp model has been vital for understanding binding, attachment 
and entry, and this model is still important for studying neutralization antibodies and viral entry.     
2.8.1.3 The HCVcc model  
In 2005 there was a major breakthrough in the research field of HCV. A HCV strain isolated from a 
patient with fulminant hepatitis in Japan was shown to replicate in cell culture and could also produce 
infectious virus particles in the supernatant (HCVcc) (134-136). The Japanese fulminant hepatitis 1 or 
JFH-1 was of genotype 2a, a unique clone with capacity of infecting hepatoma cells, chimpanzees and 
mice transplanted with human hepatocytes. Unlike HCVpp, the HCVcc could infect hepatoma cells 
resulting in production of infectious virus particles with the ability to infect naïve hepatoma cells. 
Since the discovery of JFH-1 several HCVcc constructs have been generated for different HCV 
genotypes in cell culture (137). The establishment of the HCVcc system now allows researchers to 
study all steps in the HCV life cycle as well as neutralization and the effects of antiviral drugs. 
2.8.2 In vivo models 
2.8.2.1 Chimpanzee 
 Chimpanzees are together with humans and the Tupaia (Three shrew) the only known species that are 
susceptible to HCV infection. For a long time the chimpanzee was the only model to study HCV and 
the model has been valuable in the discovery of the virus and for research about viral replication, 
transmission, and immune responses. Although the chimpanzee model has been of great value, it is 
also associated with high cost, limitation in the quantity of animals that can be used, and ethical 
problems. Other barriers are that humans and chimpanzees do not share HLA class I, and there are 
also observed differences in MHC class II (138). In addition, the disease progression differs between 
humans and chimpanzees with a lower frequency of infected chimpanzees that progress to chronicity. 
Also chimpanzees do not show signs of liver disease or tissue damage, which makes it problematic to 
study cirrhosis and hepatocellular carcinoma in this model (139, 140).  
   15 
2.8.2.2 HCV transgenic mice 
Several mouse strains transgenic for HCV proteins have been generated over the years for studying in 
vivo effects of the different HCV proteins. All HCV transgenic mice strains have the genetic material 
for HCV integrated into the genome and depending on the promoter expressed in all tissues or in 
selected tissues/organs. There have been some contradictive results regarding HCV-associated 
pathology in the transgenic mice where for example the core protein has been shown to induce 
steatosis and hepatocellular carcinoma in one study and in another study they found no pathological 
effects of transgene expression (141-143). The discrepancies may be explained by the use of different 
transgenic mouse lineages with different chromosomal integration of the transgene, expression levels 
and the genetic background of the mouse. The effects of the transgene-expression on the innate and 
adaptive immunity have also been studied. Two independent studies showed that transgenic 
expression of NS5A and NS3/4A affects the TNF-mediated hepatic apoptosis (73, 144). HCV 
transgenic mice have also been valuable in studies of vaccine development where the main purpose of 
the inserted transgene has been to mimic a chronic HCV infection with immune tolerance to the HCV 
proteins. However, there are some aspects to remember and consider when using transgenic mice. The 
transgene-expression and antigen processing may not be the same as during the natural infection. The 
protein-expression levels can be lower, undetectable or higher. Immune tolerance as a result of the 
transgene-expression can be a problem for studying immune responses and thus it is of importance to 
choose how the protein/s are expressed. Immune tolerance can possibly be avoided with delayed 
expression e.g. onset after birth (mouse major urinary protein (MUP) promoter) or if using an induced 
expression (Cre-Lox). Limitations with transgenic mouse models are that they take long time to 
generate and breed. The data generated from transgenic mice may be difficult to interpret but if the 
results are evaluated with caution the transgenic mice can generate important information. 
2.8.2.3 Transiently transgenic mice 
Transiently transgenic mice can be generated in any mouse strain by an intravenous injection in the 
tail vein. The technique was described for the first time in 1999 and was referred to as hydrodynamic 
injection (145). A hydrodynamic injection is based on a rapid (5-20 seconds) injection of a large 
volume (1,6-2,0 mL) of plasmid DNA solution in the tail vein. This injection leads to a high pressure 
in the liver and causes enlargement of the sinusoidal fenestrae. This causes an extravasation in the 
liver and by that increased permeability of the hepatocytes, 10 to 40 % of the liver cells are transfected 
(146). This model is valuable for studies of transient expression of proteins in the liver. Results from 
the transiently transgenic mice may also be compared with data obtained in stably transgenic mice. In 
the transiently transgenic model, the eradicated hepatocytes are replaced by a new non-transgenic 
hepatocyte. This means that one can use this model for studying clearance and the functionality of 
immune responses primed by immunization. Hence, this model allows evaluation of vaccine 
efficiency. It has been shown that by using this model NS5A-specific cytotoxic T cells primed in the 
periphery could enter the liver and eradicate NS5A-expressing hepatocytes (paper IV). The 
advantage of the model is that any mouse strain can be made transiently transgenic for an antigen with 
peak protein-expression levels at 48-72 hrs after injection. The main drawback is that the 
hydrodynamic injection causes transient liver damage evidenced by elevated ALT levels in serum.  
2.8.2.4 Genetically modified animals  
Wild-type mice cannot be infected by HCV but the mouse genetics can be manipulated, by knocking 
down or complementing the mouse with human exogenous factors vital for the viral life cycle. As 
 16 
described earlier, the human receptors CD81 and OCLN are essential for entry of HCV into mouse 
hepatocytes, which was recently tested in an genetically modified mouse (50). Mice with impaired 
innate immunity (STAT1-/-, IRF1-/-, IRF7-/-) and transgenic for the human entry factors (CD81, SR-
B1, CLDN1 and OCLN) were permissive for HCV infection, and allowed replication as well as virus 
production for two months (147). This is the first partially immuno-competent mouse model that 
recapitulate the entire virus life cycle. This model may possibly be used for evaluation of antiviral 
drugs.  
2.8.2.5 Mouse models with humanized liver 
Humanization of the mouse liver has been one procedure to recapitulate the HCV life cycle in a 
mouse. Several mouse strains has been established e.g. uPA-SCID, FRG, MUP-uPA and HSV-TK 
where liver injury is induced by different techniques and thereafter repopulated with human primary 
hepatocytes (148-152). The advantage with this mouse models is that they contain human hepatocytes 
and are permissive for HCV infection (153). The main weakness is that the mice are immune deficient 
in order to avoid the rejection of the engrafted human hepatocytes. Since these models lack a 
functional immune system they are not suitable for vaccine studies. However, these models are still 
valuable for studies of the viral life cycle and evaluation of antiviral drugs.  
 
 
Figure 7. Schematic illustration over the treatment of hepatitis C virus infection. 
2.9 TREATMENT 
2.9.1 Antiviral therapy 
The first treatment of HCV started already 1986 before HCV was identified and still named non-A 
non-B hepatitis. At this time the treatment for HBV was recombinant IFNα and it exerted some anti-
HBV effects. This treatment was tested for HCV as well and resulted in a cure rate of approximately 
6% (154-156). During the 1990s several studies regarding the dose and length of IFNα treatment 
resulted in adjustment of the treatment length to 48 weeks instead of 24 weeks and the cure rate 
increased to 16% (157). Monotherapy using ribavirin (RBV) was tested in the beginning of the 1990s 
and resulted in lower alanine aminotransferase (ALT) levels but had no effects on the HCV RNA 
levels (157-159). In the second half of the 1990s the first combination therapy and randomized trials 
were carried out for HCV and published. This treatment consisted of IFNα and RBV, which increased 
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the sustained virological response (SVR) after 24 and 48 weeks of treatment to approximately 34% 
and 42% respectively (160-164). Further development of the treatment, including increasing the half-
life of IFNα by pegylation (PEG-IFNα), resulted in around 39% of the patients achieving SVR after 
48 weeks of treatment and when used in combination with RBV SVRs of 54% to 56% were achieved 
(165-167). Additional optimizing since the year 2000 with PEG-IFNα adjusted to the patients weight 
on weekly basis and a fixed dose of RBV daily. Clinical trials based on PEG-IFNα and RBV reveled 
that; genotype 2 and 3 was associated with higher cure rate (76-82%) compared to genotype 1 (42-
46%), HCV RNA levels influenced the outcome of treatment with cure rates of 78% if viral load was 
<2x106 IU/mL and 42% if viral load was >2x106 IU/mL, and that genotype 2 and 3 could be treated 
during 24 weeks instead of 48 (168-170). At this time one knew that host factors were correlated to 
successful treatment response, female sex, young age, low fibrosis level and non-African American 
heritage were all in favor of clearing the infection (171-174). It took until 2003 to identify and test the 
first direct-acting antivirals (DAAs). The first ones were NS3 protease inhibitors (175). More than 20 
years after the molecular identification of HCV, DAAs became used (one protease inhibitor, 
Boceprevir or Telaprevir), in combination with PEG-IFNα and RBV to treat HCV infected patients 
(176, 177). Notably, the protease inhibitors were specific for genotype 1 and the cure rate reached 
around 75% (176, 177). Due to the severe side effects caused by INFα and RBV the goal has been to 
develop INFα-free treatment and one step was taken in 2012 with the first proof-of-concept study of 
an IFNα-free combination treatment using the NS3 protease inhibitor Asunaprevir and the NS5A 
inhibitor Daclatasvir (178). The development of new DAAs has developed rapidly with several DAAs 
on the market and several others are in clinical trials (Figures 7-8) (179-181). 
  
 Figure 8. Treatment success rate over the years. 
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The goal of an IFNα and RBV free treatment with 100% SVR are soon reached in an all oral IFNα 
and RBV free regimen using Ledipasvir (NS5A inhibitor) and Sofosbuvir (NS5B inhibitor) and a 
triple therapy with Paritavir (NS3 protease inhibitor), Ombitavir (NS5A inhibitor) and Dasabuvir 
(NS5B inhibitor) with SVR rates >90% (181, 182). The newly introduced DAAs cure most of the 
treated patients, however the new treatment do not protect against re-infection. Another limitation 
with the new DAA treatment is the high cost, which today limits the use to patients with severe liver 
disease. Another limitation with the DAAs is the risk of developing drug-resistant variants. Also, it is 
debated whether patient groups like immunosuppressed, liver-transplanted, children and pregnant 
women will be eligible for treatment using the new DAAs.  
One strategy to combat HCV would be to develop a prophylactic vaccine, which not only protect 
humans against HCV infection but also is economically beneficial for the society. An alternative 
treatment strategy for patients with HCV would be to combine DAAs with an immune stimulatory 
treatment that could also prevent patients from re-infection. Important to remember is that only 10% 
of all HCV infected patients receive any treated today (183). Hence, there are unmet needs for new 
treatment strategies that are associated with lower costs to make it possible to treat the remaining 90% 
(mostly found in low-income countries). Thus, research for alternative therapies should continue.  
2.9.1.1 Interferon-α 
Interferon-α (IFNα) is an important molecule in the innate immune system upon infection of 
intracellular pathogens. The signaling of IFNα is both autocrine and paracrine to induce an antiviral 
state of the infected and neighboring cells after binding to its receptor. The signaling cascade starting 
from the interferon receptor via the JAK-STAT pathway and results in induction of interferon 
stimulatory genes (ISGs). The IFNα does not only induce an antiviral state with promoted RNA 
degradation and inhibited protein synthesis but also activation of immune cells. The pegylated IFNα 
that is used today has a polyethylene glucol molecule conjugated to IFNα. This modification increases 
the half-life of IFNα and thereby reduces the number of injections needed (165, 184). The IFNα is 
associated with numerous side effects including severe fever, apathy, irritably, diarrhea and severe 
depression. 
2.9.1.2 Ribavirin 
Ribavirin (RBV) is a guanosine analoge with broad antiviral activity against several viral pathogens. It 
has been described that RBV has immuno-modulatory effects affecting the T helper (Th) 1/Th2 ratio 
by shifting it to a Th1 response (185-187). The antiviral genes induced by IFN have also been reported 
to be up regulated by RBV (188-191). The side effects induced by RBV are severe skin rash and 
hemolytic anemia.  
2.9.1.3 Direct-acting antivirals (DAAs) 
Protease inhibitors are targeting the NS3 serine protease of HCV. The first DAAs that were 
approved as treatment were Boceprevir and Telaprevir, which are both protease inhibitors (176, 177). 
The development of new NS3 protease inhibitors has generated improved pharmacokinetics and 
tolerability compared to Boceprevir and Telaprevir. Simeprevir was the third approved protease 
inhibitor for use in combination with IFNα and RBV (192-194). Simeprevir has also been tested 
together with Sofosbuvir in an IFNα free setting (195). Paritavir (ABT-450) is also an approved 
protease inhibitor for use in combination therapy with Ombitavir (ABT-267) and Dasabuvir (ABT-
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333) as an all-oral IFNα free treatment regimen (196, 197). Several other protease inhibitors are on 
the way to reach the market such as Grazoprevir (MK-5172), Asunaprevir (BMS-650032) and 
Faldaprevir (198-204)  
Nucleoside/nucleotide analogues are inhibitors that inhibit the NS5B protein, which is the RNA-
dependent RNA polymerase. The incorporation of this analogue results in either termination or 
introduction of mutations in the synthesized viral RNA genome. Sofosbuvir, an approved drug for 
treatment of HCV belongs to this group of DAAs and has been shown to achieve high cure rate in an 
IFNα free treatment alone and in combination with Ledipasvir and Simeprevir (195, 205-208). 
Sofosbuvir also seems to have pan-genotypic activity (209).  
Non-nucleoside analogues are instead of being incorporated in the RNA genome targeting the active 
domains of the RNA-dependent RNA polymerase and by that inhibiting its function. Included in this 
group is BMS-791325 and Dasabuvir (ABT-333). BMS-791325 has been reported to work in a 
combination study with Daclatasvir and Asunaprevir (201). Dasabuvir (ABT-333) has been approved 
as an all-oral combination with Paritavir (ABT-450) and Ombitavir (ABT-267) (196, 197).  
NS5A inhibitors bind to NS5A and interfere with its function during replication and assembly. The 
first DAAs targeting NS5A was Daclatasvir (BMS-790052), which has been tested in combination 
therapies with PEG-IFNα and RBV and as an all-oral combination with Asunaprevir and BMS-
791325 (200, 201). Ledipasvir (GS-5885) has been tested in combination with Sofosbuvir in an all-
oral IFNα free treatment with promising results (205, 206). Ombitasvir (ABT-267) also belonging to 
this group has been approved in combination with Paritavir (ABT-450) and Dasabuvir (ABT-333) 
(196, 197). Other examples of NS5A inhibitors under development are Elabasvir (MK-8742) and GS-
5816 (204, 210, 211). 
Host target antigens are targeting the host factors required during the HCV life cycle. They have a 
high barrier to resistance and are pan-genotypic, which is advantageous. Alisporivir (Debio-025) is 
one host target antigen that targets Cyclophilin A and by that inhibiting the association with NS5A 
(212, 213). Other host proteins that are interesting targets for antiviral drugs are mir122 (a micro RNA 
important for HCV replication) and SR-B1 (one of the HCV entry receptors) (214, 215)  
2.9.2 Vaccines against HCV 
There are several different kinds of vaccines today. Inactivated pathogens are used to induce 
protective antibody responses, which also are raised using proteins and protein subunits vaccines. Live 
attenuated vaccines are the most effective vaccine, which activate the immune system in a natural 
way. Genetic vaccines encoding for proteins or peptide administered as naked DNA or by using viral 
vector try to mimic a natural infection and by that induce an immune response (216). Vaccines can be 
divided in two different groups, prophylactic and therapeutic vaccines. The aim of prophylactic 
vaccines is to activate a strong, specific and effective immune response mainly focused on B cells 
(antibodies) that can neutralize the virus. Preferentially the immune activation should be remembered 
(immunological memory) meaning that Th cells are also of importance. The immunological memory 
is of vital importance for a vaccine to be able to rapidly recall the immune response when infected by 
a pathogen. A therapeutic vaccine on the other hand is aiming to activate an already existing sub-
optimal or exhausted immune response. The focus for a therapeutic vaccine is to activate a robust, 
strong, specific and effective immune response, mainly cytotoxic T cells to eradicate infected cells, 
preferably with an immunological memory to prevent re-infection. There are several both prophylactic 
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and therapeutic vaccines under development for HCV. Discussed below is the current status of the 
development of HCV vaccines.  
Chiron/Novartis (Emeryville, CA/ Basel, Schweiz) are developing a protein-based prophylactic 
vaccine including two structural proteins e.g. envelope protein 1 and 2 originating from genotype 1a. 
The vaccine is delivered in combination with the adjuvant MF59, which is an organic 30-carbon 
compound that stimulates CD4+ T cells. The results from a clinical phase I trial (13 healthy 
volunteers) show induction of cross-neutralizing antibodies that could be detected in 12 out of 13 
individuals. Interestingly, in 2 out of 13 individuals cross-neutralizing antibodies against all 7 major 
genotypes could be detected (217).  
Okarios (Rome, Italy) are developing a prophylactic/therapeutic vaccine based on the non-structural 
proteins NS3, NS4, NS5A and NS5B of genotype 1b. The vaccine is delivered using viral vectors in a 
heterologous prime-boost regimen by priming with a replicative deficient simian adenovioral vector 
(ChAd3) and boost with a Modified Vaccinia Ankara vector (MVA). The vaccine activates high levels 
of HCV-specific CD4+ and CD8+ T cells targeting multiple epitopes in a phase I clinical trial (15 
healthy volunteers). Boosting with MVA resulted in improved proliferation, polyfunctionality and 
memory responses (218).  
Transgene (Strasbourg, France) are developing a vaccine based on MVA including the NS3, NS4 and 
NS5B proteins of genotype 1b. The vaccine named TG4040 has been tested in a phase II clinical trial 
where HCV infected patients were given PEG-IFNα and RBV (n=31), PEG-IFNα, RBV and TG4040 
(n=63) or start with TG4040 and then PEG-IFNα, RBV and TG4040 (n=59). Priming with TG4040 
followed by the combination of PEG-IFNα, RBV and TG4040 resulted in the highest sustained 
virological response of 58,2%. Treatment with PEG-IFNα and RBV resulted in sustained virological 
response of 48,4%. In the group where TG4040, PEG-IFNα and RBV were administrated 
simultaneously sustained virological responses were achieved in 50,8% of the patients (219).  
ChronTech Pharma AB (Huddinge, Sweden) is developing a vaccine named ChronVac-C that is 
based on NS3 and NS4A of genotype 1a. The vaccine is delivered by an intramuscular injection in 
combination with in vivo electroporation. The combination of DNA vaccination followed by PEG-
IFNα and RBV treatment were tested in 12 patients and resulted in that 75% of the patients achieved a 
sustained virological response (220). This can be compared with 50 % sustained virological response 
in patients only treated with PEG-IFNα and RBV (165-167). 
The vaccine developed by Transgene (TG4040) and ChronTech Pharma AB (ChronVac-C) has been 
tested in combination with two doses of ChronVac-C followed by three doses of TG4040 five to 12 
weeks later in mice. The results of DNA-prime/MVA-boost showed significantly increased immune 
responses compared to administration of the two vaccines alone. High levels of polyfunctional T cells 
and induction of strong IL-2 and IFNγ levels as well as high percentage of CD8+ T cells specific for 
HCV were detected. This was a proof-of-concept study proving that the combination of two clinically 
evaluated therapeutic vaccines were better than using the vaccines individually (221).   
Inovio (Playmouth Meeting, PA) is developing a therapeutic vaccine based on a consensus sequence 
of genotype 1a and 1b. The vaccine is a DNA vaccine composed of the NS3/4A, NS4B, NS5A and 
NS5B in four different constructs administrated via intramuscular immunization in combination with 
in vivo electroporation. The vaccine has been tested in Rhesus Macaques (n=4) resulting in broad 
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responses to multiple HCV epitopes and polyfunctional T cells (222). The INO8000/VGX-6150 is 
currently tested in a phase I clinical trial in Korea where the NS5B gene has been excluded and 
NS3/4A, NS4B and NS5A are combined in one vector (223).  
Center for Genetic Engineering and Biotechnology (Havana, Cuba), is developing a vaccine named 
CIGB-230 based on the core protein and a plasmid expressing the envelope proteins E1 and E2 of 
genotype 1b have been tested in a phase I clinical trial (n=15). The results showed priming of HCV-
specific T cells responses as well as secretion of IFNγ in 73% of the previously non-responding 
patients after initial immunization (24 weeks). At the end of the treatment 46,7% of the patients had 
cellular immune response to more than one HCV protein (224).  
The above mentioned studies reveals the current status of the vaccines being developed for HCV. The 
vaccines developed by Chiron/Novartis and Okarios seems at the moment most promising. However, 
future studies will show if the vaccines live up to the expectations regarding immunogenicity and 
protection.  
 
3 GENETIC VACCINES 
There are different vaccine strategies that can be used to activate the immune system. Inactivated 
vaccines, subunit and protein based vaccines can be used and are able to induce strong B cell 
responses with production/secretion of antibodies with the ability of neutralizing the pathogen. The 
ability of inducing cellular immune response is crucial for eradication of intracellular pathogens but is 
often poor using these types of vaccines. Live-attenuated vaccines are based on weak variants of still 
functional viruses. The virus can infect and replicate in the host cell, which results in a natural 
activation of the immune system via pathogen-associated molecular patterns (PAMPs) recognized by 
pathogen recognition receptors (PRRs) (225). The immune activation following vaccination using a 
live-attenuated vaccine is potent with long-term protection, often life long e.g. measles, mumps and 
rubella vaccine (226). The use of live-attenuated viruses, as a strategy for a HCV vaccine is not 
possible due to safety concerns. The high mutation rate for HCV could result in that the weak strain is 
reverting back to a wild-type strain and establish a persistent infection. This type of strategy is 
therefore not suitable for pathogens with high mutation frequency. Genetic vaccines are also using the 
strategy of intracellular production of the vaccine antigen and are aiming at activating the immune 
response using the natural way as intracellular pathogens. One way to deliver genetic vaccines is by 
using viral vectors, which has been shown to induce effective immune responses in clinical trials e.g. 
Adenoviruses, Modified Vaccinia Ankara (MVA) (218, 219). The major challenge with viral vectors 
is the stability of the produced vaccine and problem with pre-existing immunity. Pre-excising 
immunity to the viral vector can limit the activation of immune response to the vaccine antigen. This 
can also be a problem if using the same vector for boosting as where used for the primary injection. 
The use of a heterologous prime-boost strategy may resolve this problem (218). Viral vectors have 
also shown effective boosting of the immune response after DNA immunization (221).  
3.1 EUKARYOTIC EXPRESSION VECTORS 
The DNA vaccine vector is basically a plasmid with bacterial backbone and a eukaryotic expression 
unit. The bacterial backbone is consisting of an origin of replication and a resistance gene that is 
needed to be able to produce the plasmid in bacterial cultures. The eukaryotic expression cassette 
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contains an eukaryotic promoter, Kozak sequence, the vaccine gene(s) and a poly adenylation signal. 
Regarding promoter there are different ones that can be used depending on the purpose. One often 
used promoter is the human cytomegalovirus (CMV) immediate-early promoter, which induces high 
constitutive expression in mammalian cells (227). This promoter is transcribed in most cells but with 
one drawback, it is down regulated by the cytokine IFNγ as a result of immune activation by e.g. CpG 
motifs after DNA vaccination (228, 229). Other alternatives are to use tissue-specific promoters. The 
use of tissue-specific promoters has both advantages and disadvantages. The expression of the 
vaccine-antigen is only located in the targeted tissue, which is an advantage. On the other hand the 
vaccine genes are commonly expressed in lower levels, which could be a disadvantage (230, 231). 
The Kozak sequence is important for the translation of the gene and the poly adenylation (polyA) 
signal is essential for the stability and thereby the expression of the vaccine gene (232, 233). A widely 
used polyA signal for DNA vaccines originate from the bovine growth hormone gene (BGA).  
One important factor correlated to expression and immunogenicity regarding DNA vaccines is codon 
optimization. It is a difference in codon usage in different organisms and by adapting the codon usage 
of the vaccine gene to the most commonly used codons for amino acids in humans one can increase 
both the expression levels and immunogenicity of the vaccine gene (234-237).  
3.2 DNA VACCINES 
The era of naked plasmid DNA as vaccines started during the early 1990s. It began with the first 
injection of plasmid DNA generating protein-expression in mice the year of 1990 (238). Short after, 
humoral and cellular immune activation following injection of plasmid DNA was reported (239-242). 
In 1998 came the first report regarding DNA vaccine trials in humans with a vaccine against HIV-1 
based on the Env and Gag proteins (243). The strategy has now been tested for several pathogens like 
influenza, HIV, HCV and cancer (244). Although 25 years of research has past there is still no DNA 
vaccine approved for humans. There are two approved vaccines against viral infections for use in 
animals, one for horses (Nest Nile virus) and one for salmon (infectious hematopoietic necrosis (245, 
246). So why are there no approved DNA vaccine for humans? The main reason is that the vaccine 
does not active enough potent immune response in humans. The immune response could be strong and 
protective in small animal models but low when tested in humans. The reason is most probably the 
low uptake of DNA into the cells after injection. This results in low levels of antigen expressed in the 
cells. Beside this drawback one other concern has been discussed, which is the integration of the DNA 
vaccine into the host genome. So, why still put effort into the research of DNA vaccines? The answer 
is that the positive sides of DNA vaccines are many and the negative are fewer. To overcome above 
mentioned obstacles, the research has focus on optimizing the plasmid constructs, delivery techniques 
and adjuvants. Regarding genome-integration it has been shown to be a minor concern because the 
spontaneous mutation frequency in the human genome is much higher than the integration rate of 
vaccine DNA into the humans genome (247-250). Advantages of DNA vaccines are the low cost of 
production and easy storage of the vaccine. Developing a vaccine with low cost of production and an 
easy storage at room temperature or even at higher temperatures makes it possible to use such 
vaccines also in low-income countries. The fact that DNA vaccines are considered safe with few side 
effects (local irritation and inflammation at the site of injection) and with a preferred type of immune 
activation (both humoral and cellular) highlights the importance to continue the development of DNA 
vaccines for humans (244). 
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3.3 IMMUNE RESPONSE FOLLOWING DNA IMMUNIZATION 
After injection of plasmid DNA it will be taken up by different cell types depending on the injection 
technique and site of injection (muscle, skin, mucosa and/or antigen presenting cells). Inside the cell 
the plasmid DNA is transported into the nucleus where the vaccine gene (in the eukaryotic expression 
vector) will be transcribed and translated. The expressed vaccine protein will be degraded in the 
cytosol, processed by the endogenous pathway and presented to CD8+ T cells via the MHC class I 
molecule, which almost all cells in the body express. The vaccine protein can also be presented at 
MHC class II on antigen presenting cells after engulfing the protein. Phagocytosis of vaccine protein 
released from apoptotic, necrotic or vaccine protein expressing cells are degraded and processed by 
the exogenous pathway and presented to CD4+ T cells via the MHC class II or via cross-presentation 
to CD8+ T cells via the MHC class I molecule (Figure 9). (251, 252)  
 
 
Figure 9. Priming of humoral and cellular immune responses by DNA immunization. Adapted by permission 
from Macmillan Publishers Ltd: [Nat Rev Genet.] (252), copyright (2008). 
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3.4 DELIVERY 
Several different techniques have been developed and used to optimize the delivery of DNA vaccines. 
The choice of delivery technique is one way to target a certain type of tissue and thereby activate a 
preferred type of immune response. The aim of the delivery techniques is also to increase the uptake 
of DNA vaccine into the cell and thereby increase the expression levels of the vaccine antigen. The 
delivery technique may differ in efficiency depending on which species it is tested in. Also, different 
vaccine-antigens may require different delivery techniques to obtain an optimal immune activation.  
There are different types of delivery techniques e.g. intramuscular injection, intradermal injection, 
biojector, microinjection, gene gun and in vivo electroporation (253). Delivery using intramuscular 
injection, in vivo intracellular injection device (IVIN), in vivo electroporation and prime-boost regime 
will be discussed in more detail below. 
3.4.1 Intramuscular injection (i.m.) 
Intramuscular injection of plasmid DNA is a simple procedure often performed using a mixture of 
DNA in phosphate buffered saline (PBS) solution. After injection, the myocytes passively take up the 
plasmid DNA and express the protein. The protein will then be presented as peptides on the MHC 
class I molecule on the cell surface of myocytes to T cells. Alternatively, the vaccine-antigen is taken 
up by antigen presenting cells, which migrate to the lymph nodes and present it on the MHC class II 
or via cross presentation on MHC class I to T cells (97). In smaller animals such as mice it is well 
known that a large injection volume creates a hydrodynamic pressure in the muscle, which will 
increase the DNA uptake (254). In addition, myocytes inefficiently present antigens due to low levels 
of MHC class I expression and lack of co-stimulatory molecules. To increase the immunogenicity of 
DNA vaccines in larger animals and humans the administration technique needs to be improved. 
3.4.2 In vivo intracellular injection device (IVIN) 
We have tried to improve the intramuscular injection technique by developing the in vivo intracellular 
injection device or IVIN. This injection device consists of 4-5 needles with sealed needle tips. Instead 
the shafts of the needles have holes directing the injected vaccine-solution to a defined area. The DNA 
solution is injected using a fixed pressure and targets a defined area, which standardizes the technique. 
The high-pressure obtained using this injection device increases the uptake of the DNA resulting in 
enhanced expression of the vaccine-antigen (255) (Ahlén et al., manuscript in preparation, Levander et 
al, submitted manuscript).  
3.4.3 In vivo electroporation (EP) 
The use of electroporation to transfect DNA into cells were first described in the 1980s (256, 257). 
The use of i.m. injection in combination with in vivo electroporation can enhance the uptake of 
plasmid DNA in skin and muscle cells and increase the expression of the vaccine-antigen. It has been 
debated if the DNA passively enters the cells through the pores created by the electroporation or if it is 
also transported into the cells through the pores due to the electric field (electrophoretic effect). 
Studies have shown that electrotransfer of drugs and DNA works differently (258). The pores created 
by the electroporation mediates that drugs are passively diffusing through the membrane but DNA 
seams to be to large to passively diffuse through the pores. DNA injected after electroporation while 
the cells are still permeabilized does not results in transfection of DNA into the cells, which indicates 
that the electric field is important to transfer the DNA into the cells (259). DNA is highly negatively 
charged polyanions that mediates the DNA to move in an electric field. The permeabilization of the 
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cell membrane and the electrophoretic effect are both important for the uptake of DNA by 
electroporation. Pulse pattern for optimal uptake of DNA when using electroporation is one short 
high-voltage pulse that permeabilizes the cell membrane and one long low-voltage pulse for DNA 
transfer (e.g. one pulse 0.1 ms, 800 V/cm and one pulse for 400 ms, 80 V/cm) (260). 
The parameters that can be changed in electroporation are the voltage, the number of pulses, the 
duration of the pulses and the time between the pulses. These parameters are essential for optimizing 
the delivery of DNA into cells by electroporation. The induction of cell-death and inflammation at the 
site of DNA immunization is important for a strong immune activation. The in vivo electroporation act 
as an adjuvant by enhancing the inflammatory response and infiltration of immune cells (261-263).  
Studies have shown that the integration rate is higher when comparing i.m. injection plus in vivo 
electroporation with i.m. injection alone (264, 265). However, the cells that are at an increased risk are 
though the cells that have high-uptake of the DNA. These cells are expressing high-levels of the 
vaccine antigen and thus most often efficiently eradicated by the activated host T cell response (263).  
Intramuscular injection combined with in vivo electroporation in skin and muscle has been shown to 
increase the uptake of plasmid DNA compared to regular i.m injection. Both humoral and cellular 
immune response has been shown to be effectively improved by the addition of in vivo electroporation 
in different animal models (e.g. mice, rabbits, rhesus macaques, pigs) (263, 266, 267). The use of in 
vivo electroporation when administering DNA vaccines allows the use of lower DNA doses because 
of more efficient uptake of the DNA. This is important to enable delivery of realistic DNA vaccine 
doses to humans. Additionally, the combination of the IVIN device and in vivo electroporation 
furthermore increases the uptake of plasmid DNA, which results in enhanced immune responses 
(Ahlén et al., manuscript in preparation).  
3.4.4 Prime-boost approaches  
One single injection of vaccine is seldom enough to induce protective immune responses. The 
immune system often needs multiple immunizations (e.g. booster doses), to prime strong immune 
responses. Repeated immunization of DNA, homologous boosting, does induce relatively inefficient 
immune activation in humans. Instead a more potent immune activation may be obtained using viral 
vectors. Pre-existing immunity to the viral vector can however be a problem using homologous 
boosting regimen. The pre-existing immunity could possibly clear the viral vector before the vaccine 
boosts the immune response. This could however be overcome by using a heterologous prime-boost 
strategy of one viral vector for priming and another for boosting (218). One combination that has been 
shown to work well is the combination of DNA prime and viral vector boost. This has been shown to 
be promising both in HCV and HIV vaccine studies (221, 268, 269). The DNA vaccine is easy to 
produce, store and transport, and associated with low-costs. However, combining plasmid DNA with 
viral vectors in a prime-boost regimen results in loosing some of the advantages with DNA vaccines. 
Instead DNA could be used with delivery techniques and addition of adjuvants to induce the immune 
response required. 
3.5 ADJUVANTS 
Adjuvants, from the Latin word adjuvare meaning “to help”, are almost always used in vaccines 
compositions with the aspect to help induce or shift the immune response. One of the most widely 
used adjuvants is Alum (aluminum potassium sulfate) (270). This adjuvant is used together with 
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proteins or subunit vaccines where it is mixed to an emulsion that are injected. How Alum works is 
not fully understood but it has been suggested that Alum stimulate CD4+ T cells and humoral immune 
response by interacting with membrane lipids on dendritic cells (271). Another adjuvant used is the 
MF59 that is also mixed to an emulsion with the vaccine. This adjuvant has been used to induce 
antibody responses for HCV vaccines and other vaccines like HIV and influenza (217).  
Toll-like receptor ligands can also be used as adjuvants and one TLR ligand that is indirectly used in 
all DNA vaccines is unmetylated cytidine-phosphate-guanosine (CpG) motifs. The unmetylated CpG 
motifs are detected by the TLR-9 as a defense against bacteria. Plasmid DNA is produced in bacteria 
and often contains unmetylated CpG motifs (272-274). Synthetic CpG motifs as 
oligodeoxynucleotides have also been used as adjuvants with the same mechanism of activation. Other 
TLR targets are TLR-5 and the bacterial compound flagelin and TLR-3 that is activated by double 
stranded RNA and also synthetic double stranded RNA e.g. polyinosine-deoxycytidylic acid 
(poly(I:C)) (275, 276). The triggering of TLRs and thereby the innate immune system is important for 
activation of type I IFN and the adaptive immune response.  
3.5.1 Cytokines as adjuvant 
Cytokines can be used as adjuvants to enhance the immune response to vaccine antigens. The use of 
cytokines in vaccine compositions can assist in priming a preferred type of immune response or to 
activate a specific cell type. Cytokines can be administrated as a plasmid DNA and/or as a 
recombinant protein. The addition of cytokine may improve the T cell activation and/or the 
recruitment of antigen presenting cells, both favoring an enhanced immune activation. There are in 
particular three cytokines of interest for HCV vaccines, IL-2, IL-12 and IL-21. The cytokine IL-2 is of 
importance for immunological memory and clonal expansion of T cells. In DNA vaccines IL-2 has 
been shown enhance both humoral and cellular immune responses (277, 278). The IL-12 with the 
capacity of promoting a Th1 type of immune response has been of interest as an adjuvant. The co-
expression of IL-12 has been shown to improve the immune response of DNA vaccines (255) 
(Levander et al., submitted manuscript). Notably, the level of IL-21 is elevated in patients that resolve 
acute HCV infection (104). This in combination with the capacity to induce proliferation and effector 
function of T cells makes IL-21 a highly interesting adjuvant candidate (279-281). Hence, the 
immunogenicity of DNA vaccines can be improved when used in combination with cytokines. 
However, one need to choose the cytokine to be included carefully based on which immune response 
that one want to raise (282). The half-life of cytokines is in general short and if included in a treatment 
regimen, one may need to prolong the half-life, as pegylation was necessary to prolong the half-life of 
IFNα (165, 184). Delivery of cytokine genes as DNA plasmids result in continuous expression of the 
cytokine gene at least as long time as the expression of the vaccine gene.  
3.5.2 Immune stimulatory gene sequences as adjuvant 
Numerous antigens have been evaluated for their possibilities to enhance immune activations over the 
years. One antigen that has been tested for adjuvant properties is the hepatitis B core antigen 
(HBcAg). The hepatitis B core antigen is primary presented by B cells, it binds single stranded RNA, 
and have been shown to be a strong inducer of TLR-7 (283). In paper III we have shown that human 
HBcAg act as an adjuvant to enhance the overall immune response to HCV NS3/4A. Similarly, the 
stork HBcAg has been shown to enhance the immune response of both HCV NS3/4A and NS5A. The 
major advantage of using stork HBcAg is that it will not cross react with human HBcAg and can 
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therefore be used as an adjuvant in patients previously exposed to HBV and/or infected with HBV 
(paper IV, Levander et al., submitted manuscript). 
 
4 TCR GENE THERAPY 
Activation or re-activation of T cells by vaccination is not the only strategy to activate immune 
responses. In addition one can also manipulate the immune system, for example by using gene therapy 
one can manipulate the T cell receptor (TCR) expression on effector T cells (CTLs). A strategy that 
has been shown promising is manipulation of peripheral blood mononuclear cells (PBMCs) ex vivo. 
Here, PBMCs from a patient or a matched donor are either genetically manipulated or clonally 
selected (284, 285). The selected or generated antigen-specific populations of cells are then expanded 
and re-infused into the patient.  
Therapy based on TCR gene therapy has been used with success to treat melanoma and viral 
infections such as CMV and EBV (286, 287). This treatment for viral infections targeting the liver has 
been evaluated and tested clinically for HBV with promising results (288, 289). Treatment of HCV 
with this type of therapy has not been tested clinically but is under development (paper II) (290, 291).  
Using the patients own T cells is an advantage because there will not be any problem regarding graft 
versus host rejection, which could cause unwanted effects when using donated PBMCs. Also, the T 
cells to be used for infusion are expanded outside the tolerogenic liver environment. Hence, the 
modified T cells will have cytotoxic activity against the target cells already ex vivo and do not need to 
acquire these functions in vivo. The generated/selected T cells can be infused in large quantities with 
the same specificity. Prior to infusion of the redirected T cells one may eliminate potential molecules 
or cells that suppress T cells (e.g. regulatory T cells) (292). 
There are of course some limitations with this type of therapy approach such as a high cost of 
treatment (e.g. personalized treatment), and the preparation of the redirected T cells are time 
consuming. Even though this treatment strategy is associated with some limitations it could however 
be suitable for HCV-infected patients unable of using todays treatment (IFNα, ribavirin and/or DAAs) 
due to side effects, resistance or for other reasons (e.g. patient groups like children, pregnant women, 
patients with renal failure, liver transplanted patients or already treatment experienced patients where 
it is still discussed whether they can be treated with the todays treatment or not).   
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5 AIM OF THE STUDY  
The over all aim was to develop and evaluate new therapeutic interventions for chronic hepatitis C 
virus infection.  
Specific aims in individual papers I-IV: 
Paper I 
! To develop and evaluate hepatitis C virus (HCV) non-structural (NS) 5A DNA vectors as 
potential vaccine candidates for chronic HCV infection.  
 
Paper II 
! To generate and evaluate HCV NS5A-specific T cell receptors (TCRs) for their anti-HCV 
activity.  
! To characterize TCR expression on human T cells and compare antigen specificity and 
functional avidity. 
 
Paper III 
! To investigate if heterologous T cells can help restore function in dysfunctional HCV 
NS3/4A-specific T cells during therapeutic vaccination.  
 
Paper IV 
! Characterization of T cell responses to HCV NS3/4A and NS5A to better understand the 
immune modulatory role of NS5A during immune priming and effector functions.  
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6 COMMENTS ON MATERIALS AND METHODS  
6.1 ANIMALS 
In this thesis different mouse strains have been utilized. All mice used for immunological studies had 
a H-2b background. Wild-type C57BL/6J mice were used to analyze naïve vaccine immune responses. 
Different stable transgenic (Tg) mouse strains (e.g. NS5A-Tg, NS3/4A-Tg and NS3/4A/5A-Tg) were 
used that mimic an individual with chronic HCV infection with continuous expression of the viral 
proteins. We have shown that the HCV-transgenic mice have dysfunctional T cells to HCV. Similarly, 
patients with chronic HCV infection have dysfunctional T cells. Our transgenic mice are valuable for 
analyzing vaccine-primed immune activation in an individual with dysfunctional T cell response. 
Also, mouse strains with different alterations in the immune system (e.g. IFNγR2-/-, CD4-/- and CD8-/-) 
have been used to study their effects on priming and effector functions. Mice expressing the human 
MHC class I (HLA-A2.1) instead of the mouse (H-2b) have been used to study human T cell responses 
in a mouse (HHD+ H-2Db-/- β2m-/-) (293). 
 
Tabel 1. List of mouse strains used in this thesis. 
Name of strain Background Haplotype 
Wild-type  C57BL/6J H-2b 
NS3/4A-Tg C57BL/6J H-2b 
NS5A-Tg C57BL/6J H-2b 
NS3/4a/5A-Tg C57BL/6J H-2b 
IFNγR2 C57BL/6J H-2b 
CD4-/- C57BL/6J H-2b 
CD8-/- C57BL/6J H-2b 
HHD (HHD+, H2Db-/-, β2m-/-) C57BL/6J H-2b 
NS3/4A-HHD C57BL/6J H-2b 
NS5A-HHD C57BL/6J H-2b 
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Female mice were housed 5-10 mice per cage, fed with a commercial diet and were at the age of 6-10 
weeks at the start of the experiment. Mice were housed and bred at Karolinska Institutet, Division of 
Comparative Medicine, Clinical Research Center, Karolinska University Hospital, Huddinge, Sweden 
or purchased from Charles River Laboratories (Sulzfeld, Germany) and the Jackson Laboratory (Bar 
Harbor, ME). An ethical committee for animal research at Karolinska Institutet approved all handling 
and procedure involving animals. The studies has been planed by taking the Three Rs into account 
(Replacement, Reduction and Refinement) where we have tried to find alternative methods to reduce 
and minimize suffering. We have, when possible, followed the same mouse over time by using the in 
vivo imaging system, which has reduced the number of animals used. 
6.2 PEPTIDE ANTIGENS 
Numerous peptides have been used to study T cell responses to the vaccine antigens. For NS5A there 
was no identified T cell epitope in C57BL/6J mice. We therefore performed an epitope mapping of the 
NS5A protein to identify T cell epitopes. By using 87 20-mer peptides with 15 amino acids overlap, 
the two NS5A cytotoxic T lymphocyte epitopes could be identified using an IFNγ ELISpot and their 
function could be verified by a cytotoxicity assay e.g. 51Cr release assay. (paper I) 
Mice expressing the human HLA-A2 molecule have been utilized to characterize NS5A-specific 
immune responses after vaccination as well as for generation of NS5A-specific TCRs (paper II and 
IV). We have monitored immune responses to four identified human HLA-A2 epitopes. Our results 
have revealed that immune responses were only mounted to one of the four epitopes after vaccination. 
The reason for this could be differences in epitope sequences between the original genotype (genotype 
1) and our vaccine (genotype 1b). All four HLA-A2 epitopes have shown to be present in patients 
with HCV infection.  
6.3 PLASMID VECTORS AND VACCINE OPTIMAZION  
Plasmids encoding the HCV NS3/4A and NS5A genes as well as HBcAg and SHBcAg have been 
used within this thesis. The constructs including the above mentioned genes have been design as 
single gene constructs and fusion gene constructs. The NS3/4A and NS5A proteins have important 
functions in the HCV life cycle and have a limited variability (44). Since both proteins are shown to 
be targets during HCV clearance they are also interesting as targets for HCV vaccines (103, 294). To 
enhance the immune response to NS3/4A and NS5A we included human and stork HBcAg as genetic 
adjuvants. Vaccine constructs with different modifications including addition of full-length and 
fragmented human/stork HBcAg antigens were generated. Full-length and fragmented constructs 
contain either NS3/4A proteolytic cleavage sites or self-cleaving peptide sequences to allow cleavage 
of the proteins into indicated parts (Figure 10) (295, 296). The different layout of the vaccine 
constructs will allow for different processing and degradation of the translated proteins, which will 
possibly affect the in vivo immune activation. This allows us to select the vaccine construct that most 
efficiently activates an HCV-specific immune response. The major drawback of using human HBcAg, 
as an adjuvant for the HCV vaccine is the pre-existing immunity to HBcAg in individuals exposed to, 
or infected with HBV. We solved this by instead using stork HBcAg, which has low cross-reactivity 
with human HBcAg and still is highly immunogenic.  
The codon optimized (co) NS3/4A gene is generated from a genotype 1a and has been described 
previously (234). In addition, nine fusion constructs of NS3/4A and human HBcAg were synthesized 
   31 
and used. The wild-type (wt) NS5A gene is derived from a genotype 1b isolate and described 
previously (297). Codon optimization of the wtNS5A gene and four NS5A and SHBcAg fusion 
constructs were synthesized and evaluated for immunogenicity. The plasmids were synthesized and 
generated by Retrogen (SanDiego, CA). Codon optimization is used to increase the gene expression 
by changing the codons in the vaccine to the most frequently used codons in humans.  
 
 
Figure 10. Design of HCV vaccine constructs used within this thesis.  
 
6.4 IMMUNIZATION AND DELIVERY  
As discussed earlier (Delivery) the uptake of plasmid DNA by eukaryotic cells is one parameter that 
needs to be improved to make DNA vaccines realistic for humans. One way is to optimize the 
immunization strategy using other injection techniques than regular intramuscular injection. In vivo 
intracellular injection device (IVIN) uses high pressure to localize the injected DNA solution to a 
defined area and thereby force the DNA to be taken up by the cells. Another strategy to enhance the 
uptake of DNA is to electroporate the injected area using an electroporation device. Within this thesis 
we have utilized two different devices, the MedPulser DNA delivery system (Inovio Pharmaceuticals, 
Blue Bell, PA) and the Cliniporator2 (IGEA, Capri, Italy). The MedPulser DNA delivery system is a 
pre-set system with no possibility to change the pulse pattern (two 60 ms pulses of 246 V/cm). The 
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Cliniporator2 on the other hand is more flexible and allow use of different pulse parameters. We found 
that one short high-voltage pulse followed by one long low-voltage pulse (one 1 ms 600 V/cm pulse 
and one 400 ms 60 V/cm pulse) was most efficient for uptake of our DNA vaccines. Our experience is 
that electroporation of the immunized tissue should be done directly after the immunization. One way 
to further optimize the vaccine delivery and uptake would be to combine the IVIN with 
electroporation in a one step procedure.  
In the herein described studies mice were immunized with NS3/4A- or NS5A-based DNA vaccines or 
protein/s. In all experiments the number of mice were between 5-10 per group. Protein-based 
immunization was carried out using s.c. injection (50 µg) in the base of the tail. DNA-based 
immunizations were performed in the right tibialis anterior/cranialis (TA/TC) muscle using a regular 
intramuscular injection (i.m.) or by using the in vivo intracellular injection device (IVIN) in 
combination with in vivo electroporation. Vaccine-doses ranged between 5-300 µg, and mice were 
immunized one to three times at monthly intervals. 
6.5 GENERATION OF TRANSIENTLY TRANSGENIC MICE 
Transient expression of HCV and Firefly luciferase (FLuc) genes in the liver of mice were performed 
by a hydrodynamic injection two weeks after last immunization. Injection of 1,8 mL DNA solution 
(100 µg) in the tail vein within 10 second generates a high pressure in the liver resulting in uptake of 
DNA and subsequent expression of the plasmid encoding gene (described in Model systems for HCV). 
The protein expression can be detected from 4 hours up to 2 weeks after the hydrodynamic injection 
and with the maximum expression between 48-72 hours. We evaluated our vaccines in the transiently 
transgenic mouse model since it allowed us to study priming of HCV-specific immune responses and 
in vivo killing of HCV-expressing liver cells (paper IV). A functional vaccine should be able to 
induce T cell responses that can eradicate HCV-expressing hepatocytes. Weak or undetectable levels 
of intrahepatic HCV-protein are a result of a complete eradication of HCV transfected hepatocytes. 
Hence, the model allows for detection of HCV-protein expression in liver and in liver biopsies 
determined by in vivo imaging, immunohistochemistry and western blot. This method is of importance 
to determine the functional activity of the primed T cells. However, this model does not provide any 
information about which epitopes the T cells are targeting. The in vivo imaging system make it 
possible to visualize the expression of the plasmid in the liver. It also allow us to follow the same 
mouse over time and is of course also valuable in the terms of the three Rs. Western blot analysis is 
sensitive and the easiest way of comparing HCV-protein expression in different liver samples. 
Immunohistochemistry is valuable in the way of visualizing the histology and distribution of the 
HCV-protein in the liver and also to determine inflammation and infiltration of immune cells in the 
liver. One limitation of using western blot and immunohistochemistry is that the samples originate 
from a biopsy of the liver and does not represent the whole liver. The described methods for detection 
of HCV-protein expression have been used in combination to make it easier to interpret the result 
obtained  from this model.  
6.6 TRANSGENIC MICE 
The transgenic mice used in this thesis are transgenic for the NS3/4A or NS5A genes or a combination 
thereof. The NS3/4A-Tg and NS5A-Tg mice differ in some aspects important for the interpretation of 
the results. The NS3/4A-Tg mouse strain is under the control of the mouse major urinary protein 
(MUP) promoter where the liver-specific NS3/4A-expression is turned on first two weeks after birth 
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(144). The NS5A-Tg mouse strain is expressed under the control of the mouse albumin (mAlb) 
promoter (297). The mAlb promoter generates a high liver-specific expression of the NS5A protein 
and the expression is active during neonatal development. Hence, these promoters have different 
characteristics in regards to expression levels and initiation of expression under neonatal development 
or after birth. This could result in that the NS5A-Tg mice have a more profound immunological 
tolerance compared to the NS3/4A-Tg mice. Thus, the NS3/4A-Tg mice are therefore possibly better 
in mimicking the situation during chronic HCV infection due to the onset of the HCV-expression after 
birth. 
6.7 IMMUNOLOGICAL METHODS 
6.7.1 Enzyme-Linked ImmunoSpot (ELISpot) assay 
Clearance of HCV infection has been associated with IFNγ secretion. In addition, the IL-2 cytokine is 
of importance for maintaining the T cell response and memory T cells (110, 298). We have used 
ELISpot assay to quantify the IFNγ and IL-2 secretion after immunization. This method detects 
secretion of cytokines or other secreted components triggered after re-stimulation with MHC class I or 
II peptides ex vivo. The secreted cytokine from cells are captured by anti-cytokine antibodies coated 
on the bottom of a plate, after removal of the cells the secreted cytokine can be detected via 
biotinylated antibody and visualized by avidin-HRP, resulting in spots for each cytokine producing 
cell. This method has been well accepted for immune studies in human and animals due to its high 
reproducibility and sensitive. A limitation with this method is that it only analyzes a singe cytokine at 
a time. However, today the use of fluorespot assay makes it possible to determine multiple cytokines 
in the same assay. Another aspect is the use of a mixed population of cells (e.g. spleen cells) in the 
assay setup. A cell sorting approach may solve this limitation. On the other hand, the ELISpot assay 
enable the possibility to test several antigens at the same time, which is important for analyzing 
activated immune responses after immunization.  
6.7.2 Detection of HCV-specific CTLs e.g. 51Cr release assay 
The 51Cr release assay is one standard method to detect the functionality of cytotoxic T cells ex vivo. 
Target cells used in this method are RMA-S cells that are transporter associated with antigen 
processing (TAP) deficient and thereby unable to present endogenous peptides on the MHC class I. 
The cells are instead pulsed with peptides that correspond to identified CTL epitopes resulting in that 
the target cells present the peptide. The target cells are then incubated with 51Cr, which is passively 
taken up by the target cells. After washes, the target cells can be added to the effector cells. Cytolytic 
killing of the target cells results in release of 51Cr in the medium that can be detected using a β/γ-
counter. This method provides important information about the function of activated CTLs. Data from 
this method is a valuable tool for evaluating the efficiency and functionality of vaccines. However, 
this method also has limitations, which is that the effector cells are re-stimulated with peptide or with 
cells stably expressing HCV proteins during five days in vitro. This re-stimulation outside the 
tolerogenic environment in the HCV-transgenic mice could result in high frequencies of killing that 
perhaps could be misleading and the actual in vivo effects of the killing is not so pronounced. This 
should be kept in mind when using this method and for evaluation of in vivo function of the primed 
immune response in the stable transgenic mice. Another method that can be used instead or in parallel 
is in vivo challenge with tumor cells expressing the vaccine-antigen. This model can be used to 
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monitor protection against tumor growth to investigate the functionality of vaccine-primed immune 
responses.   
6.7.3 Polyfunctional T cells and pentamer 
It has been shown that HCV-specific polyfunctional T cells are important during the clearance and 
resolution of HCV infection (105). The use of flow cytometry makes it possible to analyze cytokines 
and other molecules, both intracellular and at the cell surface. Analyzing polyfunctional T cells 
involves re-stimulation outside a tolerogenic milieu in vitro that could as in 51Cr release assay result in 
a different response compared to the in vivo situation. However, the re-stimulation is rather short (6-12 
hours). The detection of cells that binds a certain MHC class I epitope presented on a constructed 
MHC class I molecule can be done using reagents such as pentamer, tetramer or dimer X (dimer), 
where pentamers are the most stable molecules. This method is usually performed directly ex vivo and 
by that detecting HCV-specific cells as fast as possible outside the tolerogenic environment without 
any re-stimulation. Hence, this assay determines the frequency of HCV-specific T cells after 
immunization and could preferentially be used in combination with the ELISpot assay. Pentamer 
staining and polyfunctional T cell analysis provide detailed information about cell types and 
molecules expressed during the infection or immune activation.  
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7 RESULTS 
7.1 A SYNTETIC CODON-OPTIMIZED HEPTATITIS C VIRUS 
NONSTRUCTURAL 5A DNA VACCINE PRIMES POLYFUNCTIONAL CD8+ 
T CELL RESPONSES IN WILD-TYPE AND NS5A-TRANSGENIC MICE 
[PAPER I] 
In the first paper we characterized and evaluated the HCV NS5A protein as a potential vaccine 
candidate. The NS5A protein has vital functions during HCV replication and for assembly of new 
virus particles. Moreover it has been shown to interact with the host cell signaling and interfere with 
both the innate and adaptive immune system. To characterize the intrinsic immunogenicity of the 
HCV NS5A we used NS5A-DNA constructs expressing full-length wild-type (wt) NS5A, full-length 
codon optimized (co) NS5A and eight truncated wild-type NS5A constructs.  
To study the NS5A-specific cellular immune response following immunization with NS5A-DNA, we 
needed to identify NS5A CTL epitopes. A total of 87 20-mer peptides (15aa overlap) were generated 
to map NS5A CTL epitopes within the full-length NS5A genotype 1b protein. Identified peptides 
were shown to induce strong IFNγ production determined by ELISpot assay, they showed a high 
avidity in stabilization assay and was able to induce CTLs that specifically eradicated target cells in a 
51Cr release assay. Two epitopes were identified corresponding to the same sequence; one bound H-
2Db (VILDSFDPL, aa 2251-2259) and the other H-2Kb (ILDSFDPL, aa 2252-2259).  
Immunization of wild-type mice with NS5A-DNA induced high levels of IFNγ and IL-2 secretion as 
well as  T cells with cytolytic activity (Figure 11, and data not shown). Detection of IFNγ and IL-2 
secretion and cytolytic activity could also be detected in NS5A-Tg mice however at a lower 
magnitude (Figure 11, and data not shown). Our results show that the NS5A-Tg mice are 
immunologically tolerant to the NS5A protein, which mimics the situation in an HCV infected patient 
with dysfunctional immune responses to HCV.  
 
Figure 11. Quantification of NS5A-specific IFNγ-producing T cells per 106 splenocytes determined by an 
ELISpot assay. Mice were immunized i.m. once with 50 µg coNS5A-pVAX1 followed by in vivo 
electroporation of wild-type- and NS5A-Tg C57BL/6J mice. 
 
The NS5A-based vaccine was further evaluated in a tumor challenge model to investigate the potential 
of primed T cells to eradicate tumors expressing NS5A. The wtNS5A- and coNS5A-DNA vaccines 
primed T cells that efficiently could inhibit in vivo tumor growth in wild-type and immuno-tolerant 
NS5A-Tg mice. This highlights that the NS5A-DNA vaccine has the ability to prime strong T cell 
responses also in the presence of chronic HCV-protein expression.  
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Additionally, the NS5A-DNA vaccine induced polyfunctional T cells that expressed TNFα, IL-2, 
IFNγ and CD107a in wild-type mice. Lower expression levels were seen in NS5A-Tg mice, albeit 
present. Importantly, the NS5A-DNA vaccine was able to activate a polyfunctional T cell response, 
which has been shown to be of importance in resolution of HCV infection. 
7.2 TCR-REDIRECTED HUMAN T CELLS INHIBIT HEPATITIS C VIRUS 
REPLICATION: HEPATOTOXIC POTENTIAL IS LINKED TO ANTIGEN 
SPECIFICITY AND FUNCTIONAL AVIDITY [PAPER II] 
In the second paper we generated antigen-specific polyfunctional T cells via TCR redirection. These 
TCRs were created by NS5A-DNA immunization in HLA-A2 transgenic mice, re-stimulated in vitro 
(NS5A1992-2000) and thereafter purified CD8+ T cells were fused with Thymoma cells (BW5147). The 
sequence of the TCR α- and β-chain were codon optimized, linked together with a F2A self-cleaving 
sequence and inserted in a retroviral vector used for gene transfer of the TCRs. The NS5A TCR 
transfected human T cells had a lower functional avidity and needed a higher concentration of peptide 
to be stimulated compared to the high avidity NS3 TCRs (NS31073-1081) generated previously. 
Transfection of NS3 and NS5A TCRs into T cells from healthy blood donors and HCV infected 
patients resulted in IFNγ production. This was evaluated after stimulation with NS3 and NS5A 
peptides and with non-transfected T cells as controls.  
Polyfunctional T cells have been shown to be associated with control and clearance of HCV infection. 
We therefore tested the polyfunctionality of the T cells transfected with the NS3 and NS5A TCRs. T 
cells transfected with NS3 TCR were considered polyfunctional with expression of TNFα, IL-2 and 
IFNγ in both healthy blood donors and HCV infected patients. It was shown that 50 % of the T cells 
expressing the NS3 TCR were triple or double positive and the other 50 % were single positive for 
one of the tested cytokines. On the other hand, the majority of NS5A TCR transfected T cells 
expressed a single cytokine.  
We also tested the cytolytic activity of the TCRs by analyzing the CD107a, which is a marker for 
recent lytic activity by perforin-granzyme mediated killing. This resulted in different profiles for the 
NS3 and NS5A TCRs. The CD107a was up regulated on the NS3 TCR transfected T cells but not on 
NS5A TCRs. Interestingly, even though the NS3 and NS5A effectively inhibit HCV replication in 
human hepatoma cells they do so with different mechanisms.  
7.3 HETEROLOGOUS T CELLS CAN HELP RESTORE FUNCTION IN 
DYSFUNCTIONAL HEPATITIS C VIRUS NONSTRUCTURAL 3/4A-
SPECIFIC T CELLS DURING THERAPEUTIC VACCINATION [PAPER III] 
The chronic HCV infection is associated with impaired function of HCV-specific T cells expressing 
exhaustion markers on the cell surface. It has been shown that robust and broad T cell responses are 
essential to resolve chronic HCV infection and we therefore investigated if recruitment of healthy 
heterologous T cells could help in priming more potent NS3/4A-specific T cells.  
First we tested if depletion of regulatory T cells or inhibitory molecules could restore the T cells 
function in immune-tolerant NS3/4A-Tg mice with impaired T cell responses compare to wild-type 
mice. The result showed that depletion of regulatory T cells, inhibitory molecules or multiple 
immunizations could restore the T cell function in NS3/4A-Tg mice. This indicates that NS3/4A-Tg 
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mice have impaired T cells caused by immune modulatory effects similar to those seen in patients 
with chronic HCV infection. Importantly, the T cells are not depleted by clonal deletion.  
The hepatitis B core antigen (HBcAg) is known as a strong activator of the immune system via TLR-
7. We therefore tested if this highly immunogenic protein could help to recruit healthy heterologous T 
cells and improve the T cell response when co-expressed with NS3/4A. The vaccine constructs 
including NS3/4A were modified by introduction of the adjuvant gene HBcAg. Fusion constructs 
including NS3/4A and human HBcAg were designed. Introduction of NS3/4A cleavage sites in the 
proteins resulted in fragmented versions of the HBcAg antigen. The introduction of cleavage sites in 
the NS3/4A-HBcAg vaccine constructs aimed to promote a different post-translational processing of 
the expressed proteins. 
Results obtained using the different constructs revealed that human HBcAg weakly improved the T 
cell responses to NS3/4A in wild-type mice. Interestingly, the addition of human HBcAg significantly 
improved the NS3/4A-specific T cell response in the NS3/4A-Tg mice. Furthermore, we established a 
new NS3/4A-Tg mouse that expressed the human HLA-A2 instead of the mouse H-2b. This mouse 
was used to study HLA-A2 NS3/4A-specific T cell responses in the presence of intrahepatic NS3/4A-
expression. Immunization revealed that NS3/4A-DNA vaccines containing human HBcAg could 
restore the NS3/4A-specific T cell response whereas vaccines without HBcAg failed.  
7.4 FUNCTIONAL DIFFERENCES IN HEPATITIS C VIRUS NONSTRUCTURAL 
(NS) 3/4A- AND NS5A-SPECIFIC T CELL RESPONSES [PAPER IV]  
The NS5A protein is one of the least characterized proteins of HCV. In this study we wanted to 
compare the T cell response to HCV NS3/4A and NS5A with the aim of improve our understanding 
of the immune modulatory role of NS5A during immune priming and effector functions. We therefore 
further developed our NS5A-DNA vaccine (from paper I) and compared the NS3/4A and NS5A 
proteins in regards to priming of HCV-specific T cell responses. Priming of NS3/4A and NS5A T cell 
responses were in this study shown to be dependent on different molecules and cells of the immune 
system.  
In this study we could show that the NS5A-DNA vaccine required much higher doses compared to 
NS3/4A-DNA to induce HCV-specific immune responses analyzed by IFNγ and IL-2 production and 
quantification of HCV-specific CD8+ T cells. We know from previous studies that NS3/4A-specific T 
cell responses are dependent on CD8+ T cells but not CD4+ T cells and that depletion of regulatory T 
cells expressing CD25 and GITR greatly improves the immune response in NS3/4A-Tg mice (234). 
Priming of NS5A-specific T cells were here shown to be dependent on both CD4+ and CD8+ T cells 
and surprisingly depletion of regulatory T cells expressing CD25 and GITR did not improve the 
priming of NS5A-specific T cells. The cytokines IL-12 and IL-21 are known to enhance the T cell 
responses primed by DNA vaccines (255, 277-281). The IL-12 has been tested in combination with 
NS3/4A with promising results but neither IL-12 nor IL-21 improved the NS5A-specific T cell 
response.  
However, addition of stork hepatitis B core antigen (SHBcAg) could significantly enhance the 
immunogenicity of NS5A in wild-type- and NS5A-Tg mice. The vaccine based on NS5A-SHBcAg 
was in this study shown to be highly immunogenic in mice expressing human HLA-A2 instead of the 
mouse H-2d (Figure 12).  
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Figure 12. Quantification of NS5A-specific IFNγ-producing T cells after immunization of 50 µg NS5A-DNA 
vaccine with or without SHBcAg. Data presented as IFNγ-producing T cells per 106 splenocytes determined by 
an ELISpot assay.  
 
In paper III we showed that there are differences in the functional properties between NS3 and NS5A 
TCR transfected T cells. In this study we compared the production of IFNγ and the inhibition of HCV 
replicon RNA replication. The NS3 TCR transfected T cells produced high levels of IFNγ and 
efficiently inhibited HCV replicon RNA replication whereas the NS5A TCR transfected T cells 
produced lower levels of IFNγ and less efficiently inhibited HCV replicon RNA replication.  
In addition, differences between NS3/4A and NS5A were also found when analyzing the ability of 
primed T cells to clear intrahepatic NS3/4A- and NS5A-expression in transiently transgenic mice. 
Clearance of NS3/4A-expressing hepatocytes has been shown to be dependent on CD8+ T cells and 
IFNγR2 but not CD4+ T cells (66). Clearance of NS5A-expressing hepatocytes required both CD4+ 
and CD8+ T cells, but not IFNγR2, which is a distinct difference from NS3-specific T cells.  
 
  
   39 
8 DISCUSSION 
The hepatitis C virus is a major cause of liver disease and a major global health problem. It is 
estimated that around 130-150 million people are chronically infected, which corresponds to around 2 
% of the world population. The infection becomes chronic in around 80 % of the cases and these 
patients may over time develop fibrosis with an increased risk of cirrhosis and hepatocellular 
carcinoma. There has been a revolution regarding treatment for HCV with numerous direct-acting 
antiviral drugs (DAAs). Even though the new treatment has a cure rate above 90 % there are still 
obstacles with the treatment. Firstly, the treatment is associated with high-costs, which result in 
limited or no use in resource-poor countries. It is estimated that only 10 % of all chronic HCV infected 
patients get any treatment (183). Secondly, there are still discussions whether patient groups like 
children, pregnant women, liver transplanted patients, patients with renal failure or already treatment 
experienced patients will be treated with the new antiviral compounds. Lastly, the treatment based on 
DAAs does not protect against re-infection. It is desirable with a future treatment that also protect 
against re-infection. To reduce HCV globally there is a need of treatment associated with lower costs. 
A treatment that activates the HCV-specific T cell response will most probably also be beneficial for 
patients with drug resistant virus, non-responder patients and patients that discontinued treatment due 
to side effects.  
This thesis focuses on the HCV NS3/4A and NS5A proteins known to be important for the viral 
propagation. The NS3/4A protein has essential functions as protease and helicase in the viral life 
cycle. The NS5A protein is important for the viral replication and particle assembly as well as to 
interact with key players in the host cell signaling pathway. Furthermore, both NS3/4A and NS5A 
have been shown to interfere with the innate and adaptive immune system. Studies have demonstrated 
that NS3/4A and NS5A harbor T cell epitopes important for resolution of HCV infection. This, in 
combination with the fact that NS3/4A and NS5A also works as target for DAAs, makes them 
interesting as a vaccine candidates and targets for T cell based therapies.  
Paper I: In the first study, we generated a HCV NS5A-based genetic vaccine of genotype 1b. The 
gene sequence was codon-optimized to maximize the expression level of the vaccine antigen in 
human cells. In addition, we also generated a wild-type (wt) construct and eight truncated constructs. 
First, we had to identify murine CTL epitopes within NS5A. The use of overlapping peptides resulted 
in identification of two functional epitopes in domain two of NS5A. These epitopes belonged to two 
different H-2b alleles even though they corresponded to the same amino acid sequence. The identified 
epitopes induced IFNγ and IL-2 production and the primed specific CTLs had lytic activity.  
The NS5A-based vaccines were tested in wild-type and immuno-tolerant (NS5A-Tg) mice with 
activation of IFNγ and IL-2 production and quantifiable numbers of NS5A-specific CD8+ T cells. The 
responses were in general weaker, but detectable in the NS5A-Tg mice. Our results highlights that the 
NS5A-Tg mice have tolerized T cell responses to NS5A, and thereby serves as a relevant model for 
studying NS5A-specific immune responses. Importantly, our NS5A-DNA vaccine could prime 
NS5A-specific immune response in the NS5A immuno-tolerant transgenic mouse model.  
Furthermore, the NS5A-DNA vaccine was also tested for functionality in a tumor challenge model. 
This model is based on a tumor cell line expressing NS5A. This model allowed us to investigate the 
protection against in vivo tumor growth after immunization. The NS5A-DNA vaccine was shown to 
protect wild-type mice and to a lower extent also immuno-tolerant NS5A-Tg mice. The tumor 
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challenge model was also used to characterize to which regions of the NS5A protein the NS5A-
specific T cells were directed. Our results revealed that the C-terminal part of NS5A was shown to 
mediate the protection.  
In addition to showing that the NS5A-DNA vaccine induced functional T cell responses, we analyzed 
whether the vaccine also could activate HCV-specific polyfunctional T cells. HCV-specific 
polyfunctional T cells have been shown to be of importance in the resolution of HCV infection (105). 
Our NS5A-DNA vaccine could prime polyfunctional T cells producing TNFα, IL-2, IFNγ and 
expressing CD107a in both wild-type and immuno-tolerant NS5A-Tg mice after a single 
immunization. All together, this shows that our NS5A-DNA vaccine is able to prime polyfunctional 
NS5A-specific T cells with lytic activity in the presence of chronic NS5A expression in the NS5A-Tg 
mice.  
Paper II: In the second paper we used the NS5A-DNA vaccine (developed in paper I) to activate 
human NS5A-specific T cells in HLA-A2-Tg mice. The NS5A-specific T cells were used to generate 
NS5A-specific TCRs. The generated NS5A TCRs were compared with the previously generated NS3 
TCRs for functional activity. The TCRs were specific for two T cell epitopes (NS31073-1081 and 
NS5A1992-2000) known to correlate with resolution of HCV infection, (294, 299).  
The NS3 and NS5A TCR-transfected T cells were shown to respond with IFNγ production upon 
stimulation with the respectively antigens. The NS5A TCRs did though need higher concentration of 
the antigen to respond. Differences between the TCRs were also seen in the polyfunctionality where 
the NS3 TCRs was associated with polyfunctional T cells with 50 % of the TCR-redirected T cells 
positive for two or three of the following cytokines; TNFα, IL-2 and IFNγ. The NS5A TCR-redirected 
T cells were instead single positive and mainly producing IFNγ or TNFα. The effector function of the 
TCRs were also different where the high avidity NS3 TCRs were shown to perform cytolytic effector 
functions while the low avidity NS5A TCRs instead performed non-cytolytic effector functions.  
High avidity CTLs are sensitive to antigen-induced cell death but effective in clearance of virus 
infected cells. Control of HCV infection has been associated with selection of high avidity T cells, 
polyfunctionality and potent viral suppressive activity (300, 301). Low avidity CTLs on the other hand 
has been proposed to control disease progression during virus infection (302). Low avidity T cells 
have also been described to suppress viral replication in target cells without cytolytic effector function 
but instead with secretion of IFNγ and TNFα. This has been shown for HCV and HBV infection and 
mediated by virus-specific CD8+ T cells (303, 304). The use of low-avidity TCRs in treatment of 
chronic HCV could be an advantage due to clearance of HCV infected cells without inducing any liver 
damage (303).  
Mouse and human TCRs have shown high tolerability in humans as a therapy against cancer (292, 
305, 306). A broad polyfunctional immune response to HCV is required for viral clearance (102, 103). 
According to this, using one or two TCRs to transfect human PBMCs may not be enough to obtain 
eradication of the viral infection. However the use of multiple TCRs may be an effective strategy to 
clear the infection. The strategy of redirecting HCV-specific T cells could be of interest for patients 
who have failed antiviral treatment or are infected with a drug resistant virus.  
Paper III: In the third paper the aim was to enhance the immunogenicity of the previously developed 
NS3/4A-DNA vaccine by the addition of immune stimulatory gene-sequences. The immune system of 
patients with chronic HCV infection is exhausted and their T cells are commonly dysfunctional (100, 
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108, 111, 113, 115, 307). A majority of the HCV-specific T cells during chronic HCV infection are 
impaired. Hence, to successfully activate potent HCV-specific T cell responses in individuals with 
chronic HCV infection the immune priming must be highly immunogenic. This may be obtained by 
recruiting healthy heterologous T cells to the site of priming. This has previously been shown for non-
responders to the hepatitis B vaccine. Immunization of the previous non-responders using both the 
hepatitis A and B vaccine induced a 95% seroconversion to HBcAg (308).  
In this study we used NS3/4A-Tg mice known to have dysfunctional NS3/4A-specific T cells, which 
is similar to what have been shown for humans with chronic HCV infection. Immunization of the 
NS3/4A-Tg mice using the NS3/4A-DNA vaccine showed an impaired phenotype of the primed T cell 
responses. Interestingly, the NS3/4A-specific T cell responses could partly be restored by depletion of 
regulatory T cells or cells expressing inhibitory molecules revealing that the impaired T cell responses 
were due to dysfunctional T cells and not explained by clonal deletion.  
We have in this and previous studies shown that the NS3/4A-DNA vaccine is priming potent NS3/4A-
specific T cell responses in wild-type mice and weaker T cell responses in immuno-tolerated NS3/4A-
Tg mice. The addition of human HBcAg gene-sequences to the NS3/4A-DNA vaccine resulted in  
weakly improved NS3/4A-specific T cell responses in wild-type mice. On the other hand, when 
human HBcAg and NS3/4A was co-expressed in the NS3/4A-Tg mice we found a significant 
improvement of the primed T cell response, evidenced by increased NS3/4A-specific IFNγ-producing 
T cells. The use of immune stimulatory gene-sequences to recruit healthy heterologous T cells to the 
site of immune activation was in this study effective and could reactivate the dysfunctional T cells and 
improve the overall immune response.  
Since around two billion people have been exposed to hepatitis B, the use of human HBcAg may not 
be optimal as a vaccine adjuvant. Thus, one alternative is to use HBcAg from another species, such as 
the avian HBcAg. To avoid problems with pre-existing immunity we decided to replace the human 
HBcAg with avian HBcAg (e.g. stork HBcAg). Importantly, there are no or little cross reactivity 
between human and stork HBcAg.  
Paper IV: In the fourth paper we combined the NS5A-DNA vaccine from paper I and the adjuvant 
evaluated in paper III. This new improved NS5A-DNA vaccine was in this study compared to the 
previously generated NS3/4A-DNA vaccine. We were interested in which factors that are required for 
NS5A-specific T cell priming. We also compared NS3 and NS5A TCR-redirected human T cells for 
anti-HCV activity in vitro as described in paper II, to address functional differences in NS5A and 
NS3/4A T cell priming.  
We have previously shown that NS5A-DNA could induce NS5A-specific T cell responses in wild-
type and NS5A-Tg mice. Next we analyzed if the immunogenicity of the NS5A could be further 
improved. We evaluated the vaccine dose, co-expression with cytokine genes, and the importance of 
CD4+ and CD8+ T cells for immune priming. We found that activation of NS5A-specific T cell 
responses was highly dose dependent. In addition we could show that NS5A-specific immune 
responses are dependent on both CD4+ and CD8+ T cells for priming. The immune response could not 
be adjuvanted by addition of IL-12 and/or IL-21. Notably is that the NS3/4A-DNA vaccine primed 
immune responses in the absence of CD4+ T cells, and the immune response could be adjuvanted by 
IL-12 (234) (Levander et al., submitted manuscript). Depletion of regulatory T cells or inhibitory 
molecules did not improve the NS5A-specific immune activation. On the other hand, we have shown 
that NS3/4A-specific T cell responses can be improved by Treg depletion.  
 42 
Interestingly, the addition of immune stimulatory gene-sequence (e.g. stork HBcAg) increased the 
overall immune response to both NS5A and NS3/4A. The adjuvant effect was weak in wild-type mice 
but more evident in the respective transgenic mouse linage. We have recently shown that NS3/4A-
specific T cell responses can be adjuvanted by both human and stork HBcAg (Levander et al., 
submitted manuscript). Stork and human HBcAg show very limited cross reactivity, thus stork 
HBcAg may be used in patients with chronic HBV infection. Our results revealed that the NS5A-
stork-HBcAg DNA vaccine was superior the NS5A-DNA vaccine alone in humanized mice (e.g. 
HLA-A2-Tg mice).  
In addition, we compared the functional properties of the T cell responses primed after NS3/4A- and 
NS5A-DNA immunization. The NS3/4A-specific T cell response is known to be dependent on IFNγ, 
CD8+ T cells but not CD4+ T cells (66, 309). This is a distinct difference from primed NS5A-specific 
T cell responses that requires both CD4+ and CD8+ T cells for priming but not IFNγ. Moreover, we 
generated TCRs with specificity for NS3 and NS5A. We found functional differences in avidity, 
induction of IFNγ-production and the TCRs effector function. The NS3 TCRs (high avidity) with 
cytolytic activity was shown to inhibit in vitro HCV RNA replication. In contrary, the NS5A TCRs 
(low avidity) performed non-cytolytic activities that could inhibit HCV RNA replication. In 
conclusion, the HCV-specific immune response may be dependent on both these types of primed 
responses.  
In summary, we have developed a NS5A-DNA vaccine with the capacity of inducing both IL-2 and 
IFNγ. Vaccine activated NS5A-specific CD8+ T cells were polyfunctional and immune responses 
could be detected in both wild-type and NS5A immuno-tolerant mice. The NS5A-DNA vaccine was 
also analyzed in a tumor challenge model was primed NS5A-specific T cells protected against tumor 
growth. The NS5A-DNA vaccine was also used in the generation of NS5A-specific TCRs. The NS5A 
TCRs (low avidity) produced IFNγ and could inhibit HCV RNA replication. The inclusion of an 
immune stimulatory gene-sequences (human or stork HBcAg) in our vaccine compositions was shown 
to adjuvant both the NS3/4A- and NS5A-specific T cell response. Finally, a comparison of NS3/4A 
and NS5A reveled that the two vaccines can induce effector function but requires different factors for 
immune priming. The development of new alternative treatment strategies for HCV is needed to be 
able to treat patients in both high- and low-income countries. 
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9 GENERAL CONCLUSION 
 
! Genetic immunization using HCV NS5A efficiently primed NS5A-specific T cell responses.  
 
! Two HCV NS5A-transgenic mouse models (stable and transient) were developed and 
successfully used for evaluation of vaccine primed immune responses. 
 
! Development of HCV-specific TCRs revealed correlation between antigen specificity and 
antiviral activity.  
 
! Genetic immunization using HCV NS3/4A and NS5A revealed functional differences in the T 
cell response. Both priming and effector functions differed among the two antigens. 
 
! Healthy heterologous T cells could restore dysfunctional HCV-specific immune responses.  
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10 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Hepatit C är ett virus som infekterar levern och sprids främst via kontaminerat blod. I Sverige 
introducerades screening för hepatit C under tidigt 1990-tal vilket har resulterat i att viruset idag 
huvudsakligen sprids mellan personer som injicerar narkotiska preparat. I låginkomstländer där 
kontroll av blod och blodprodukter samt sterilisering av medicinska instrument fortfarande är 
undermåliga sprids hepatit C fortfarande inom sjukvården. Förutom ovan nämnda smittvägar så är 
även tatueringar och piercing med oren utrustning möjliga smittkällor.  
I Sverige finns idag ca 40 000 personer som lever med hepatit C virus (HCV) infektion och i hela 
världen mellan 130-150 miljoner vilket motsvarar omkring 2 % av den totala befolkningen. Hos 20 % 
av de som infekteras med HCV lyckas immunförsvaret själv läka ut infektionen och personen blir 
frisk. I de resterande 80 % av fallen blir infektionen kvarvarande (e.g. kroniska). I dessa fall 
misslyckas immunförsvaret med att kontrollera viruset vilket bland annat kan förklaras av att viruset 
är så föränderligt. Detta leder hela tiden till att nya virusvarianter framträder som immunförsvaret 
måste bekämpa.  
Sedan identifieringen av HCV år 1989 har behandlingen utvecklats och de senaste åren har det skett 
en revolution gällande virushämmande läkemedel för HCV. De tidiga behandlingarna av HCV med 
IFNα resulterade i att 6 % blev friska, med kombinationen av IFNα och ribavirin 50 % och IFNα och 
ribavirin i kombination med de första virushämmande läkemedlen resulterade i ca 75 % blev botade. 
Interferon-α (IFNα) är en komponent i det naturliga försvaret som kroppen själv producerar som svar 
på en virusinfektion. IFNα kan även tillverkas och ges som läkemedel. Ribavirin är ett annat 
läkemedel som stör/förhindrar produktionen av nytt virus. Tyvärr så är behandlingar med IFNα och 
ribavirin associerade med flera besvärliga biverkningar och därför har målet varit att hitta alternativa 
behandlingar för att slippa använda dessa läkemedel. De nya virushämmande läkemedlen som finns 
idag har en utläkningsfrekvensen på över 90 % och är fria från IFNα och ribavirin samt ges i 
tablettform oftast en gång per dag.  
Trots den nya behandlingens höga utläkningsfrekvens finns det flera nackdelar med behandlingen. Ett, 
den höga kostanden för läkemedlen som medför att användandet av dessa blir restriktivt till de svårast 
sjuka. Två, det finns patientgrupper som inte kan ta dessa läkemedel på grund av resistensutveckling, 
det vill säga patienter som utvecklar motståndskraft mot läkemedlet, och även de som inte tål 
behandlingen av olika orsaker. Dessutom är det ovisst huruvida barn, gravida och patienter oförmögna 
att svara på behandlingen ska behandlas med dessa läkemedel. Tre, de nya virushämmande 
läkemedlen ger inget skydd mot att smittas av HCV igen. I dagsläget får endast 10 % av alla världens 
HCV infekterade personer någon behandling och faktum är att de flesta infekterade finns i 
låginkomstländer vilket innebär att det finns ett stort behov av nya alternativa behandlingar som är 
mer kostnadseffektiva.  
I nuläget finns inget vaccin och inte heller någon behandling som ger skydd mot återinfektion. Vi 
arbetar med att utveckla behandlingar som på ett effektivt sätt aktiverar immunförsvaret hos de som 
bär på HCV och därigenom kan utplåna HCV. Ett problem är att viruset hela tiden förändrar sin 
arvsmassa vilket göra att immunförsvaret ofta har problem att känna igen delar av viruset. Det är 
därför viktigt att rikta behandlingen mot de delar av viruset som förändras minst. Vi har baserat våra 
behandlingar till två virusstrukturer som förändrar sig mindre jämfört med andra regioner av HCV. 
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Dessa delar är de icke-strukturella proteinerna 3/4A och 5A. Dessa två proteiner är livsviktiga för att 
viruset ska kunna producera nya viruspartiklar.  
Vår behandlingsstrategi baseras främst på genetiska vaccin där genen (e.g. arvsmassan) för det 
aktuella proteinet används som vaccin. Vaccinet som består av cirkulärt DNA innehåller vaccingenen 
och detta DNA kan odlas upp i stora mängder i bakterier. När vaccinet ges till människa kommer 
genen att utryckas till protein i cellerna. Cellerna kommer då att bryta ner proteinet och visa det för 
immunförsvaret på cellytan. Det här är samma sätt som celler annars använder för att presentera egna 
och främmande proteiner från virus och bakterier för immunsystemet. Det gör att immunförsvaret blir 
aktiverat på ett naturligt sätt, nämligen att både de celler som dödar infekterade celler (mördar T 
celler) och de celler som hjälper till att rikta immunförsvaret i rätt riktning (T hjälpar celler) aktiveras. 
Vårt vaccin har testats i möss där muskeln i ett av bakbenen injiceras med vaccin. Genen som kommer 
från viruset har modifierats så att den så lätt som möjligt uttrycks i djur och människa samt att den ges 
i kombination med en teknik som heter in vivo elektroporering. Tekniken syftar till att öppna upp 
porer i muskelcellerna och att dra in vaccin-DNAt i cellerna. Den ökade mängden vaccin-DNA som 
kommer in i cellerna genom in vivo elektroporering samt den optimeringen av vaccinet vi gjort ökar 
uttrycksnivåerna av protein i muskeln. Detta leder till ökad presentation av protein-delar för 
immunförsvaret och därmed får vi en starkare aktivering av immunförsvaret. Vi har även undersökt 
vilka komponenter som är viktiga och nödvändiga för att få en stark aktivering av immunförsvaret. 
Våra resultat visar att vaccinet som baseras på NS3/4A är beroende av T mördar celler för sin funktion 
medan NS5A vaccinet är beroende av både T mördar celler och T hjälpar celler. Genom att jämföra 
våra två vaccinkandidater har vi ökat vår förståelse om dessa proteiner samt deras förmåga att aktivera 
immunförsvaret. Vi har även lärt oss hur vi kan optimera dem för att få en starkare immunaktivering. 
Studier har visat att de T celler som känner igen viruset är utmattade och kan därför inte utplåna de 
infekterade cellerna. Vi har då försökt att utveckla våra vaccin genom att tillsätta vissa komponenter 
som ökar aktiveringen av immunförsvaret (adjuvant). Ett adjuvant som visade sig fungera för båda 
vaccinen var tillsatsen av en gen från ett annat virus (hepatit B virus). Genom att använda denna gen i 
kombination med våra vaccin-gener så har vi kunnat få en betydligt starkare aktivering av 
immunförsvaret vilket ökar möjligheterna till att immunförsvaret kan utplåna HCV.  
Vår forskning syftar till att ta fram alternativa behandlingar mot HCV för att nå fram till så många 
patienter som möjligt. Ett genetiskt vaccin är billigt att producera och har en bra stabilitet vilket 
möjliggör transport och förvaring i rumstemperatur. Dessa egenskaper medför möjlighet att skapa ett 
behandlande vaccin som kan användas på bred front i så väl höginkomstländer respektive 
låginkomstländer. 
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